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The synthesis of nitrogen-containing heterocycles is important due to the fact that 
many biologically active molecules contain these motifs. Over the past 10 years, the 
Wolfe group has developed efficient and highly diastereoselective Pd-catalyzed 
carboamination reactions for the synthesis of pyrrolidines, ureas, pyrazolidines, 
isoxazolidines, morpholines and benzodiazepines in good yields. These transformations 
involve syn-insertion of an alkene into a Pd–N bond of an intermediate Pd-amido species 
followed by CC bond forming reductive elimination. However, enantioselective 
variants that involve syn-aminopalladation are rare, and only two reports of 
enantioselective syn-aminopalladation have appeared in the literature.  
An enantioselective synthesis of 2-(arylmethyl)- and 2-
(alkenylmethyl)pyrrolidines via Pd-catalyzed alkene carboamination reactions of N-Boc-
pent-4-enylamines and aryl or alkenyl bromides is described. These transformations 
generate enantiomerically enriched pyrrolidine products with up to 94% ee. The 
application of this method has been demonstrated for the concise asymmetric synthesis of 
phenanthroindolizidine alkaloid ()-tylophorine. Studies on asymmetric Pd-catalyzed 
desymmetrization reactions for the formation of cis-2,5-disubstituted pyrrolidines are also 
described.   
A new enantioconvergent route for the asymmetric synthesis of (+)-aphanorphine 
has been accomplished using an asymmetric carboamination/Friedel-Crafts alkylation 
strategy. Enantioselective Pd-catalyzed carboamination reaction of a racemic γ-
 xiii
aminoalkene derivative provides a 1:1 mixture of enantiomerically enriched 
diastereomers. This mixture of diastereomers is then converted to one stereoisomer via 
Friedel-Crafts reaction, which generates a quaternary stereocenter. Three additional steps 
provide the natural product.   
Lastly, studies on asymmetric Pd-catalyzed reactions for the enantioselective 
synthesis of imidazolidin-2-ones, isoxazolidines, pyrazolidines and tetrahydrofurans are 
described. Promising ligand scaffolds have been identified and promising leads are being 




1.1 Introduction to Wolfe Group Chemistry 
The syn-insertion of alkenes into palladium-nitrogen bonds has been implicated as 
a key step in a number of important metal-catalyzed processes1 including alkene 
carboaminations,2 diaminations,3 and oxidative aminations.4 Over the past few years, the 
Wolfe group has developed efficient Pd-catalyzed carboamination reactions for the 
synthesis of N-heterocycles such as pyrrolidines, isoxazolidines, pyrazolidines, 
imidazolidin-2-ones, piperidines, and morpholines (Table 1-1).5 The attractive features of 
this carboamination reaction are: 1) up to 2 stereocenters are generated with concomitant 
formation of a CN and CC bond; 2) good yields and diastereoselectivity; and 3) the 
facile generation of analogs by varying the aryl/alkenyl coupling partner.   
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Table 1-1. Pd-Catalyzed Carboamination Reactions 
 
1.2 Mechanistic Considerations  
The Pd-catalyzed carboamination reaction proceeds via the catalytic cycle shown 
below in Scheme 1-1. Oxidative addition of an aryl halide to Pd(0) precatalyst I-1 
generates palladium complex I-2. Pd(0) is either generated from Pd2(dba)3 or a Pd(II) 
source such as Pd(OAc)2, which is reduced to Pd(0) in situ.6 Base-mediated 
deprotonation of the γ-amino alkene I-3 and subsequent transmetallation affords Pd-
amido complex I-4. Coordination and syn-insertion of the alkene into the PdN bond via 
I-5 generates Pdalkyl intermediate I-6. Finally, CC bond forming reductive 
elimination affords the desired pyrrolidine I-7 and regenerates the Pd(0) catalyst (Scheme 
1-1).  
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Pd(II) precatalyst + Ln
 
The high diastereoselectivity of these reactions arise from minimization of A(1,3)-
strain and 1,3-diaxial interactions.1a,1b For example, carboamination reaction of N-Boc-
pent-4-enylamine derivatives I-8 and I-15 proceed in good selectivity for cis-2,5-
disubstituted pyrrolidines and trans-2,3-disubstituted pyrrolidines respectively (Scheme 
1-2).2e The conversion of I-8 to cis-2,5-disubstituted pyrrolidine I-11 can be rationalized 
via transition state I-9, which would generate I-10 and reductive elimination generates 
pyrrolidine product I-11. Cyclization through I-9 is favored because transition state I-12 
suffers from A(1,3)-strain between the C1-phenyl group and the N-Boc protecting group. 
Alternatively, substrates I-15 bearing allylic substituents provide trans-2,3-disubstituted 
pyrrolidine products I-18 via transition state I-16, which orient the C3-methyl group in 
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the more favorable pseudo-equatorial position to minimize A(1,3)-strain and 1,3-diaxial 
interactions.  
Scheme 1-2.2e Stereochemical Rationale for Diastereoselectivity 
 
1.3 Enantioselective Alkene Functionalization Reactions  
Enantioselective variants that involve syn-aminopalladation of alkenes are rare 
and to this date, only a few asymmetric Pd-catalyzed aminopalladation reactions that 
likely proceed through syn-insertion have been reported.7,8,9 Enantioselective Pd-
catalyzed carboamination reactions between aryl/alkenyl halides and alkenes bearing 
pendant nitrogen atoms have not been previously reported. 
1.31 Enantioselective Diamination Reactions 
In 2007, Shi reported the first catalytic asymmetric diamination of conjugated 
dienes and trienes for the synthesis of imidazolidin-2-ones.7a As shown below, treatment 
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of di-tert-butylaziridinone I-19 and conjugated diene I-20 with a catalyst system 
generated from Pd2(dba)3 and tetramethylpiperidine-derived phosphoramidite ligand I-
L1, gave diamination product I-21 in 91% yield and 92% ee (Scheme 1-3). A variety of 
dienes and trienes were employed, and the diamination reaction was highly selective for 
the internal alkene of the diene or triene. The steric bulk of the nitrogen substituent on I-
L1 was imperative for high reactivity and enantioselectivity. For example, the use of a 
dimethylamine derivative of I-L1 only provided < 1% conversion.  
Scheme 1-3. Asymmetric Diamination of Conjugated Dienes and Trienes 
 
This reaction is believed to proceed via oxidative addition of I-19 to Pd(0) to 
generate Pd(II) intermediate I-22, which undergoes syn-aminopalladation to afford 
allylpalladium complex I-23. Reductive elimination from I-23 provides I-21 and 
regenerates the Pd(0) catalyst. Mechanistic studies on Pd(0)-catalyzed diamination of 
conjugated dienes with Pd(PPh3)4 support the formation of a four-membered Pd(0) 
intermediate I-22.7c  
The imidazolidin-2-one products can be further manipulated for the synthesis of 
optically active diamine compounds (Scheme 1-4).7a From imidazolidin-2-one I-24, 
deprotection with TFA and hydrochloric acid, followed by basic workup yields diamine 
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I-26 without erosion of enantioselectivity. I-24 can also be oxidized to generate 
imidazolidin-2-one derivative I-27. Selective mono deprotection of I-27 provides 
opportunities to introduce other functional groups onto the nitrogen atom of I-28.  
Deprotection of I-27 with TFA and treatment with 2 N HCl yields functionalized diamine 
I-29 in nearly quantitative yield.  
Scheme 1-4. Deprotection and Further Elaboration of Cyclic Urea I-24  
 
Chiral N-heterocyclic carbenePd(0) complexes have also been effective for 
asymmetric diamination reactions of conjugated dienes and trienes (Scheme 1-5).7b For 
example, treatment of di-tert-butylaziridinone I-30 and diene I-31 with NHC-Pd(0) 
complex afforded imidazolidin-2-one I-32 in 88% yield and 76% ee. As compared to the 
Pd-phosphoramidite catalyst system described above, NHCPd(0) complexes can 
potentially serve as better catalysts, since these catalysts are potenitally more stable and 
subtle changes to the N-heterocyclic carbene structure seem to effect reactivity and 
enantioselectivites to a greater degree.   
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Scheme 1-5. Chiral N-Heterocyclic CarbenePd(0) Catalyzed Diamination 
5 mol % NHC-Pd(0)
15 mol % NaOtAm



















1.32 Enantioselective Oxidative Amidation 
Stahl recently reported a highly enantioselective intramolecular Wacker-type 
oxidative cyclization of internal alkenyl sulfonamides using a (pyrox)Pd(II)(TFA)2 
catalyst and O2 as the sole stoichiometric oxidant for the synthesis of enantioenriched 
pyrrolidines (Scheme 1-6).8 As shown below, substrates such as I-33 were converted to I-
34 using a catalyst system of Pd(TFA)2 and pyridine-oxazoline ligand (S)-I-L2 in good-
to-excellent yields and high enantioselectivities. Preliminary computational studies have 
revealed that the reaction may proceed through a rate-limiting and enantio-determining 
transition state such as I-35, where the vinylic methyl group in I-35 is oriented 
downward, away from the phenyl group, which leads to differentiation of the two 
enantiotopic faces of the alkene in the insertion step.  
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Scheme 1-6. Asymmetric Aerobic Oxidative Amidation 
 
Catalyst-controlled stereoselective cyclization was also demonstrated for a 
number of chiral substrates (Scheme 1-6). For example, treatment of chiral substrate I-36 
with the (R)- or (S)-enantiomer of I-L2 provided cis-2,4-disubstituted pyrrolidine I-37 or 
trans-2,4-disubstituted pyrrolidine I-38 in good yield and high diastereoselectivity 
respectively.  
1.33 Enantioselective Oxidative Cascade Cyclization 
Yang and coworkers reported the first enantioselective oxidative tandem 
cyclization for the synthesis of indolines, which proceeds through a mechanism involving 
aminopalladation followed by carbopalladation of the second alkene.9b As shown below, 
2-allylaniline derivative I-39 was converted to I-40 through the treatment of I-39 with a 
catalyst system composed of Pd(OAc)2 and tert-butyl quinoline-oxazoline ligand I-L3 
with molecular oxygen as the sole oxidant afforded indolines I-40 in good yield and high 
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ee (Scheme I-7). The oxidative cascade cyclization typically yielded one diastereomer 
and the olefin geometry of the substrate was discovered to control the relative 
stereochemistry of the product. In addition, the stereochemical outcome of I-40 supports 
syn-aminopalladation as the only mechanistic pathway that leads to the product.  
Scheme I-7. Pd(II)/t-Bu-Quinoline-Oxazoline Catalyzed Cascade Cyclization  
 
 
1.34 Copper(II)-Catalyzed Intramolecular Carboamination of Alkenes 
Chemler reported the first catalytic and enantioselective Cu-catalyzed syn-
aminocupration of unactivated alkenes for the synthesis of chiral cyclic sulfonamides.10a 
As shown in Scheme 1-8, exposure of various N-(arylsulfonyl)-pent-4-enylamines I-43 
with a catalyst system of Cu(OTf)2 and bisoxazoline ligand I-L4 provided I-44 in good 
yields and enantioselectivites. A copper(II) source of Cu(OTf)2 provided higher 
enantioselectivities than Cu(EH)2, due to better ligand chelation. MnO2 oxidant was 
imperative for higher catalyst turnover. Furthermore, changing the solvent from toluene 
to trifluorotoluene decreased formation of hydroamination side product. These chiral 
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sulfonamides (I-44) can also be converted to 2-(arylmethyl)pyrrolidines via reductive 
deprotection of SO2 under dissolving metal conditions.  
Scheme 1-8. Enantioselective Cu(II)-Catalyzed Carboamination  
 
The catalytic cycle and rationale for enantioselectivity is described below in 
Scheme 1-9.10b,11 Treatment of N-(arylsulfonyl)-pent-4-enylamine I-46 with copper(II) 
catalyst I-45 affords aminocuprate intermediate I-47. Intermediate I-47 is converted to I-
49 through a presumed rate and enantiodetermining syn-aminocupration via transition 
state I-48. In this transition state, steric interactions are minimized where the N-
substituent is facing in the opposite direction of the closest oxazoline phenyl substituent. 
CC bond formation occurs via homolysis of the unstable carboncopper(II) I-49 bond 
to generate primary carbon radical intermediate I-50, which adds into the tethered aryl 
ring. Oxidation and rearomatization of the resulting aryl cation produces chiral 
sulfonamide I-51. The Cu(I) species (I-52) is reoxidized and transmetallation of the 
substrate regenerates active Cu(II) catalyst I-47.  
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Scheme 1-9.10b Catalytic Cycle and Transition State Model 
 
Chemler and coworkers have obtained evidence in support of this mechanism by 
trapping radical intermediate I-50 with TEMPO for an enantioselective aminoxygenation 
reaction (Scheme 1-10). Treatment of I-53 with a catalyst system of Cu(OTf)2, cis-4,5-
disubstituted phenyl bisoxazoline derivative I-L5 and 3 equivalents of TEMPO provided 
I-54 in 97% yield and 86% ee. TEMPO alone could promote copper catalyst turnover.  
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Pyrrolidine products such as I-54 were converted to aminoalcohol I-55 by reduction with 
Zn, or amino aldehyde derivative I-56 by oxidation with m-CPBA.  
Scheme 1-10. Enantioselective Copper-Catalyzed Intramolecular Aminooxygenation 
 
1.4 Other Enantioselective Pd-Catalyzed Reactions that Involve Alkene-
Aminopalladation 
There are several other synthetically useful enantioselective alkene 
aminopalladation reactions that proceed via anti-aminopalladation or an aminopalladation 
mechanism that has not been stereochemically defined. These reactions are attractive 
methods for the enantioselective synthesis of N-heterocycles such as imidazolidin-2-ones, 
oxazolidinones, amides, and β-amino acid derivatives. 
A non-oxidative approach toward the asymmetric synthesis of N-heterocycles is 
Pd(II)-catalyzed alkene aminopalladation involving substrates bearing allylic acetates. In 
contrast to oxidative amination reactions described in Scheme 1-6, these transformations 
are terminated by β-elimination of the allylic acetate. These reactions no longer require 
oxidant, but substrates become more complex. Nonetheless, treatment of I-57 with 
catalytic amount of FOP catalyst affords ureas, amides and oxazolidinones (I-58) in high 
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yield and enantioselectivities. Aminopalladation of I-57 proceeds through Pdalkyl 
intermediate I-59 and subsequent β-acetoxy elimination provides N-heterocycles I-58 and 
regenerates the active catalyst (Scheme 1-11).12  




























X = NH (96% yield, 90% ee)
X = CH2 (95% yield, 90% ee)
X = O (98% yield, 93% ee)
 
Sasai and coworkers have reported a highly enantioselective aminocarbonylation 
reaction for the synthesis of bicyclic β-amino acid. A catalyst system of 
[Pd(MeCN)4](BF4)2 and spiro bisisoxazoline ligand I-L6 was effective for the conversion 
of I-60 to I-61 in 89% yield and 88% ee (Scheme 1-12).13 The authors propose a 
mechanism that involves coordination of the alkene and nucleophilic attack to generate 
alkylpalladium complex I-62. CO insertion provides acylpalladium intermediate I-63, in 
which ring closure via nucleophilic trapping of I-63 by the tethered tosylamide yields I-
61 and Pd(0), which is reoxidized by benzoquinone to regenerate the Pd(II) catalyst. 
However, the reaction requires low temperatures and long reaction times (ca. 7 days), 
there is potential for other spiro bisisoxazoline ligands to be employed as effective 
ligands for enantioselective oxidative cyclization reactions.  
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10 mol % [Pd(MeCN)4](BF4)2
11 mol % I-L6, CO (1 atm)
p-benzoquinone, MeOH, -40 C
89% yield, 88% ee




































Over the past few years, the syn-insertion of alkenes into palladium-nitrogen bonds 
has been an important method for the synthesis of N-heterocycles. However, asymmetric 
variants are rare and there are only a few reports of enantioselective alkene 
functionalization reactions that proceed via syn-aminopalladation or other 
aminopalladation mechanisms. Our recent success in diastereoselective palladium-
catalyzed carboamination reactions prompted us to explore an asymmetric variant. The 
following chapters in this thesis will describe the following: 1) our development of an 
asymmetric Pd-catalyzed carboamination reaction for the synthesis of 2-(arylmethyl)- 
and 2-(alkenylmethyl)pyrrolidines; 2) preliminary studies on asymmetric Pd-catalyzed 
desymmetrization reactions; 3) the enantioconvergent synthesis of (+)-aphanorphine via 
Pd-catalyzed carboamination reaction; and 4) preliminary studies on asymmetric Pd-
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Chapter 2 
Enantioselective Synthesis of 2-Substituted Pyrrolidines via Asymmetric Pd-
Catalyzed Carboamination Reactions 
2.1 Introduction 
2-(Arylmethyl)pyrrolidines are prominent features of many natural products such 
as phenanthroindolizidine alkaloid tylophorine (II-1), homoharringtonine (II-2), preussin 
(II-3), and 3-benzomorphan aphanorphine (II-4), which exhibit anti-tumor, anti-
leukemia, anti-fungal and analgesic activity respectively (Figure 2-1).1  
Figure 2-1. 2-(Arylmethyl)pyrrolidine Containing Natural Products 
 
The 2-(arylmethyl)pyrrolidine motif is found in pharmaceutical leads II-5, and their 
absolute stereochemistry can have striking effects on biological activity.2 For example, 
the R-enantiomer of pyrrolidine II-5 is a potent 5-HT6 agonist, whereas the S-enantiomer 
displays antagonistic activity (Figure 2-2). 5-HT6 serotonin receptors have been 
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implicated in anxiety, depression, cognition, and learning.3 Binding studies have also 
shown a high affinity of this receptor for certain anti-psychotic and anti-depressant 
drugs.4  
Figure 2-2. 5-HT6 Receptor-Active Compounds 
 
2-(Arylmethyl)pyrrolidines have also served as organocatalysts for enantioselective 
Michael additions.5 For example, Kotsuki and coworkers have developed chiral 
pyrrolidine catalyst II-L1 that contain an attached pyridine base, which facilitates 
enamine formation from ketone II-6 and acts as a proton shuttle. The pyridinium ring 
also effectively shields one side of the enamine forcing the nitroolefin acceptor II-7 to 
approach from the nonshielded side, providing highly enantioselective and 
diastereoselective formation of Michael adducts such as II-8 (Scheme 2-1). 




Due to the importance of enantiomerically enriched 2-(arylmethyl)pyrrolidines in 
natural products, pharmaceutical leads, and organocatalysts, methods to synthesize 2-
(arylmethyl)pyrrolidines are of interest to the synthetic community. 
2.2 Recent Methods for the Asymmetric Synthesis of 2-(Arylmethyl)pyrrolidines 
One of the most common methods for the synthesis of enantioenriched 2-
(arylmethyl)pyrrolidines involves the addition of Grignard reagents to proline derivatives 
followed by reduction of the ketone (Scheme 2-2).6 Commercially available D-proline II-
9 can be protected with ethyl trifluoroethanoate and converted to the mixed anhydride II-
10 in 65% yield. Treatment of II-10 with various Grignard reagents followed by 
hydrogenolysis in acidic EtOH affords 2-(arylmethyl)pyrrolidines II-11 in low to 
moderate yields.  
Scheme 2-2. Synthesis of 2-(Arylmethyl)pyrrolidines via Grignard Reactions 
 
Jackson and coworkers have recently developed a new method for the synthesis of 
2-(arylmethyl)pyrrolidines involving in situ trapping of N-Boc-2-pyrrolidinylmethylzinc 
iodide with aryl iodides (Scheme 2-3).7 Treatment of N-Boc-prolinol (II-12) with PPh3, I2 
and imidazole produces alkyl iodide II-13 in 89% yield. N-Boc-2-pyrrolidinylmethylzinc 
iodide is generated in situ from II-13, which undergoes Negishi coupling with an aryl 
iodide in the presence of catalytic Pd2(dba)3 and SPhos to afford N-Boc-2-
(arylmethyl)pyrrolidines II-14 in low to good yields. Attempts to generate the proline-
derived zinc reagent separately were unsuccessful, as the reagent underwent rapid 
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elimination to give the corresponding γ-amino alkene. The variable yields of 2-
(arylmethyl)pyrrolidines II-14 are due to the instability of these alkyl zinc reagents and 
substrate-dependent rates of Negishi cross-coupling.  
Scheme 2-3. Negishi Cross-Coupling for the Enantioselective Synthesis of 2-
(Arylmethyl)pyrrolidines 
 
As previously discussed in Chapter 1, Chemler has developed a copper-catalyzed 
carboamination reaction of N-sulfonyl alkenes II-15 for the synthesis of chiral 
sulfonamides II-16, which can be desulfonylated to provide the corresponding 2-
(arylmethyl)pyrrolidines in good yields and enantioselectivities (Scheme 2-4).8 These 
reactions are rare examples of enantioselective carboamination involving alkene insertion 
into a CuN bond.  
Scheme 2-4.  Enantioselective Copper-Catalyzed Intramolecular Carboamination 
 
Over the past few years, our group has developed a practical and efficient method 
for the diastereoselective synthesis of substituted pyrrolidines via Pd-catalyzed 
carboamination reactions between aryl/alkenyl bromides and γ-aminoalkene derivatives, 
which proceed in good yields and high diastereoselectivity.9 Our success in this endeavor 
prompted us to investigate an asymmetric variant of these transformations that would 
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generate enantiomerically enriched 2-(arylmethyl)pyrrolidines in a concise manner.  The 
rest of Chapter 2 will describe our studies on the enantioselective synthesis of 2-
(arylmethyl)- and 2-(alkenylmethyl)pyrrolidines via asymmetric Pd-catalyzed 
carboamination reactions. 
2.3 Project Goals and Previous Studies 
As shown below in Scheme 2-5, our goal was to couple amine II-17 with an aryl or 
alkenyl halide for the synthesis of enantioenriched 2-(arylmethyl)pyrrolidines II-18. To 
accomplish this task, we needed to address the following: 1) identify a chiral ligand that 
would induce asymmetry in the CN bond forming step (syn-aminopalladation); 2) 
optimize the reaction conditions for high yields and enantioselectivities; and 3) 
demonstrate utility through application of the asymmetric carboamination reaction 
toward the synthesis of a natural product.  
Scheme 2-5. Synthetic Strategy 
 
2.31 Previous Studies by Dr. Qifei Yang 
Preliminary work on asymmetric Pd-catalyzed carboamination reactions was 
initially conducted by Dr. Qifei Yang, who was a former post-doctoral researcher in the 
Wolfe group. After a brief survey of ligands, Dr. Yang found that treatment of N-Phenyl-
pent-4-enylamine II-19 and 2-bromonaphthalene with a catalyst system composed of 
Pd2(dba)3 and (S)-Quinap facilitated formation of pyrrolidine II-20 in 30% yield and 10% 
ee (Scheme 2-6).10 The reaction was a proof of concept that asymmetric induction, albeit 
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low, could be achieved through the use of a chiral ligand. We wanted to explore this 
reaction in greater detail by examining the coupling of N-Boc-pent-4-enylamine 
derivatives with a variety of other chiral ligands.  
Scheme 2-6. Previous Studies by Dr. Qifei Yang 
 
2.4 Substrate Synthesis 
A variety of substituted N-Boc-pent-4-enylamines were synthesized according to 
literature procedures.9f 4-penten-1-ol derivatives (II-2123) were converted to N-Boc-
pent-4-enylamines (II-24a26) via nucleophilic displacement of the alcohol, hydrazine 
monohydrate cleavage of the phthalimide and Boc protection of the free amine. N-Boc-
pent-4-enylamines (II-24a26) were obtained in good yields ranging from 69-81% yield 
(Scheme 2-7).  
Scheme 2-7. Synthesis of N-Boc-pent-4-enylamine Derivatives 
 
2,2-dimethyl- and 2,2-diethoxy-N-Boc-pent-4-enylamines II-24b and II-24c were 
synthesized according to a procedure developed by Michael and coworkers.11  
Deprotonation of 2,2-disubstituted nitrile (II-27 and II-28) with LDA produced the 
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corresponding lithium carbanion, which was allowed to react with allyl bromide to 
produce alkenyl derivatives II-29 and II-30 in good yield. LAH reduction of the nitrile 
followed by addition of Boc2O provided 2,2-disubstituted N-Boc-pent-4-enylamines II-
24b and II-24c in moderate yield (Scheme 2-8).  
Scheme 2-8. Synthesis of 2,2-Dimethyl- and 2,2-Diethoxy-N-Boc-pent-4-enylamines 
 
2.5 Optimization Studies: Ligand Screen/Ligand Synthesis 
In our initial experiments, we examined the coupling of N-Boc-pent-4-enylamine 
II-24a with 2-bromonaphthalene (Table 2-1). It was our hope that with the appropriate 
chiral ligand and reaction conditions, II-31a would be formed with some degree of 
asymmetric induction. Our prior studies with achiral catalysts indicated that chelating 
ligands with relatively large bite angles (e.g., dpe-phos or dppb)9e provided satisfactory 
yields of racemic products. Thus, we examined a series of chiral bis-phosphines for the 
carboamination reaction (Table 2-1). Unfortunately, ligands such as (S)-BINAP (II-L3) 
or (S)-PHANEPHOS (II-L7), which possess bite angles similar to dpe-phos and dppb, 
provided poor yields of II-31a, low enantioselectivities, or both. Other bis-phosphines 
such as (S,S)-BDPP (II-L9) and (R,R)-NORPHOS (II-L11) provided similar results. In 
summary, bidentate bis-phosphine ligands provided low conversion and 
enantioselectivity of pyrrolidine II-31a. 
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Table 2-1. Bidentate Phosphine Ligand Screena,b,c 
2 mol % Pd(OAc)2
4 mol % Ligand




































































a Conditions: Reactions were conducted on a 0.15 mmol scale with 1.0 equiv substrate, 1.2 equiv 2-
bromonaphthalene, 1.2 equiv NaOtBu, 2 mol % Pd(OAc)2, 4 mol % ligand, toluene (0.15 M), 110 °C, 14 h. b






A majority of the ferrocene-derived ligands examined provided no trace of 
pyrrolidine product (II-31a), as decomposition of the starting material was often 
observed (Table 2-2). However, Josiphos-derived ligands II-L17 and II-L20 provided II-
31a in good yield. A comparison of these ligands seems to suggest that the substituent on 
the phosphorous atom has a dramatic impact on the yield of the reaction. Unfortunately, 
low enantioselectivity was observed for this class of ligands.  
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Several other monodentate ligands were screened as shown below in Table 2-3. 
BINOL-derived monodentate ligand (R)-MOP (II-L22) and chiral phosphite ligands (II-
L25, II-L26 and II-L27) provided low yields, low enantioselectivities or both. Menthol-
derived ligand (S)-NMDPP (II-L24) provided a promising lead with formation of II-31a 
in 76% yield and 18% ee.  Ligands that are known to be effective for enantioselective 
Tsuji-Trost allylation (II-L28), copper-catalyzed carboamination reactions (II-L29), and 
oxidative cyclizations (II-L30) provided no desired product.  
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We then elected to investigate chiral phosphoramidite ligands, as several recent 
studies have demonstrated these ligands are highly effective in other Pd-catalyzed alkene 
addition reactions.12 As shown in Table 2-4, promising results were obtained with 
BINOL-derived phosphoramidites (S,S,S)-II-L41 and (S,R,R)-II-L42. Phosphoramidites 
composed of (+)-bis[(R)-1-phenethyl]amine derivatives were important for 
enantioselectivities, as decreased ee and lowered yields were observed for ligands 
containing achiral amine derivatives (II-L31−II-L36). Furthermore, the yield and 
enantioselectivity of the carboamination reaction was sensitive to minor changes to the 
structure of the ligand. For example, phosphoramidite ligand II-L38, which contained a 
trans-2,5-disubstituted pyrrolidine, resulted in decomposition of the starting material, 
whereas dimethoxy-substituted ligand II-L40 provided pyrrolidine product II-31a in 
lower yield (14% yield), but similar ee as ligand (S,R,R)-II-L42 (65% ee).  
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Table 2-4. Phosphoramidite Ligand Screena,b,c 
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From the results shown in Table 2-4, phosphoramidites composed of (+)-bis[(R)-
1-phenethyl]amine were important for enantioselectivity. We wanted to explore the effect 
of substitution on the binaphthol backbone of phosphoramidite ligand II-L42 and decided 
to synthesize a variety of binaphthol derivatives (Scheme 2-9).13 Starting from (S)-
BINOL (II-L43), protection of the diol as a methoxy methyl ether proceeded in nearly 
quantitative yield to afford protected BINOL derivative II-L44. Treatment of II-L44 with 
2 equivalents of n-BuLi followed by addition of MeI and then MOM-deprotection 
afforded methyl substituted BINOL derivative II-L45 in 70% yield over 2 steps. To 
install aryl substitution at the C3 and C3’ positions, II-L44 was first lithiated with n-BuLi 
and then quenched with 1,2-dibromotetrachloroethane to provide brominated analog II-
L46. Coupling of II-46 and PhB(OH)2 in the presence of catalytic Pd(PPh3)4, Na2CO3 in 
DME at 90 °C and deprotection of the methoxymethyl ether afforded II-47 in 63% yield 
over 2 steps. To functionalize the C6 and C6’ positions of the BINOL backbone, II-L43 
was exposed to neat bromine at -78 °C, which facilitated selective bromination. MOM-
protection of diol II-L48 provided II-L49 in nearly quantitative yield. Coupling of II-
L49 with PhB(OH)2 followed by deprotection of the methoxymethyl ether yielded II-L50 
in 60% yield over 2 steps. With binaphthol derivatives II-L45, II-L47 and II-L50 in 
hand, we were ready to synthesize analogs of phosphoramidite ligand (S,R,R)-II-L42.   
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1) 10 mol % Pd(PPh3)4
PhB(OH)2
99% yield
63% over 2 steps
NaH
90% yield 63% yield
70% over 2 steps
1) 10 mol % Pd(PPh3)4
PhB(OH)2
















Na2CO3, DME, 90 °C
 
 Phosphoramidite ligands II-L51II-L55 were synthesized in moderate yields 
according to a slightly modified procedure reported by Alexakis (Table 2-5).14 It was 
important to let the diol, PCl3 and Et3N stir for 30 minutes to ensure that the 
chlorophosphite had been formed.  Then, addition of the chiral amine-HCl salt in CH2Cl2 
afforded the phosphoramidite ligand in moderate yield. We found that CH2Cl2 was 
imperative for reactivity and solubility of the amine-HCl salt, since employing other 
procedures involving tetrahydrofuran or toluene failed. Higher yields of the 
phosphoramidite ligands could also be obtained when the free amine was used or by 
following a more rigorous procedure developed by Rajanbabu.15 
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Table 2-5. Synthesis of Phosphoramidite Analogs 
 
  As shown in Table 2-6, the newly synthesized phosphoramidite ligands were 
examined. When ligands II-L51 and II-L52 were employed, low yields and 
enantioselectivities were observed, which suggests that steric components at C3 and C3’ 
negatively effect reactivity and selectivity. We then examined 6,6’-disubstituted ligand 
II-L53, but no increase in ee was observed. Changing the backbone from (S)-BINOL to 
2,2’-biphenol (II-L54) decreased reaction yield and enantioselectivity (39% yield and 
40% ee), which implies that the chirality of the BINOL backbone is important. (S)-H8-
BINOL derived ligand II-L55 provided promising results with enantioselectivities up to 
77% ee. Further exploration led to the discovery that spriobiindane-derived 
phosphoramidite (R)-Siphos-PE (II-L56) provided useful levels of enantioselectivities 
(81% ee).  
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Table 2-6. Other Phosphoramidite Ligand Screena,b 
 
2.51 Optimization of Reaction Conditions 
 With a suitable ligand in hand, we sought to optimize the reaction conditions by 
first examining the effect of N-protecting groups on the carboamination reaction. The 
coupling of a variety of N-protected-pent-4-enylamine derivatives and 2-
bromonaphthalene were surveyed in the presence of Pd(OAc)2, (R)-Siphos-PE and 
NaOtBu (Table 2-7). N-aryl derivatives II-32a-e provided pyrrolidines II-33a-e in good 
yields, but no enantioselectivity was observed. Relative to the N-Boc protecting group, N-
aryl protecting groups are less sterically demanding which could be responsible for the 
 35
reduction in ee. From these results, the N-Boc protecting group appears to be a key 
component for enantioselectivity in this reaction. 
Table 2-7. N-Protecting Group Studya,b 
2 mol % Pd(OAc)2
4 mol % (R)-Siphos-PE
NaOtBu, Toluene, 110 °C
N




















Cbz (II-32e) No Rxn (II-33e)c,d -6
II-24a, II-32a-e
Boc (II-24a) 50% (II-31a) 81%1
a Conditions: Reactions were conducted on a 0.15 mmol scale with 1.0 equiv substrate, 1.2 equiv
2-bromonaphthalene, 1.2 equiv NaOtBu, 2 mol % Pd(OAc)2, 4 mol % ligand, toluene (0.15 M),
110 °C, 14 h. b Enantiomeric excess was determined by chiral HPLC analysis. c 2 equiv of
Cs2CO3 was used. d Use of dioxane as the solvent yielded similar results.
II-31a, II-33a-e
 
 The effect of other reaction parameters such as base and solvent were explored. 
Efforts to employ weak bases such as Cs2CO3 and K3PO4 led to low conversion and in 
the latter case, diminished enantioselectivities. Stronger bases such as KOtBu increased 
decomposition of starting material (Table 2-8). Ethereal solvents such as tetrahydrofuran, 
dioxane, and diglyme were examined, but produced pyrrolidines in lowered yields.  
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Table 2-8. Base Screena,b 
 
 Other palladium sources were surveyed but did not influence the 
enantioselectivity of the reaction. We elected to use Pd2(dba)3 as a general palladium 
source, since it was most effective across a broad range of coupling partners. It is 
important to note that the palladium source could be optimized for individual aryl halides 
for higher yields of pyrrolidine product if needed. Finally, a lower reaction temperature 
of 90 °C was optimal for reaction conversion. The reaction could also be conducted at 
lower temperatures (65 °C), but longer reaction times were needed. In general, the 
enantioselectivity remained constant across a range of temperatures (65−110 °C).  
 We found that the use of 2.5 mol % Pd2(dba)3 as a precatalyst, a ligand:metal ratio 
of 1.5:1, and a lowered reaction temperature of 90 °C produced II-31a in 78% yield and 
82% ee. Before examining the scope of the reaction, we wanted to screen other 
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commercially available spirobiindane-derived ligands (Table 2-9). (S)-Siphos-PE (II-
L57), the diastereomer of (R)-Siphos-PE (II-L56), provided pyrrolidine product II-31a in 
modest yield under the reaction conditions, but with opposite enantioconfiguration. From 
this result, it seems there is a matched pair for (R)-Siphos-PE and the spirobiindane diol 
is responsible for absolute configuration. Conversely, phosphite and phosphine ligands 
(R)-SHIP (II-L58) and (R)-SITCP (II-L59) produced lower yields and 
enantioselectivities. These results are consistent with previous ligand screens, which 
demonstrate the importance of the spirobiindane backbone and chiral amine on 
enantioselectivity.  
Table 2-9. Spirobiindane-Derived Ligand Screena,b,c 
2.5 mol % Pd2(dba)3
7.5 mol % Ligand











47% yield, 25% ee
II-L59
(R)-SITCP
















55% yield, -78% ee
Ph
Ph
a Conditions: Reactions were conducted on a 0.2 mmol scale with 1.0 equiv substrate, 2.0 equiv 2-
bromonaphthalene, 1.0 equiv NaOtBu, 2.5 mol % Pd2(dba)3, 7.5 mol % ligand, toluene (0.2 M), 90 °C,
12-15 h. b Enantiomeric excess was determined by chiral HPLC analysis. Negative ee values indicate




2.6 Enantioselective Synthesis of 2-Substituted Pyrrolidines 
The optimized conditions were effective for carboamination reactions between 
substrates II-24a-c and different aryl and alkenyl halide electrophiles. As shown in Table 
2-10, these transformations for the coupling of aryl bromides proceeded in moderate to 
good yield and provided the desired products with ee’s ranging from 7292%. Although 
most experiments were conducted on a small scale, the coupling II-24a with 2-
bromonaphthalene gave nearly identical results on both small (0.2 mmol) and larger (1.0 
mmol) scales (II-31a). Electron-donating groups on the aryl bromide were well tolerated 
as enantioselectivities up to 92% ee were observed (II-31j), although this method was 
less effective with electron-poor aryl bromides. For example, reactions of tert-butyl p-
bromobenzoate (II-31g) and m-bromobenzotrifluoride (II-31k) proceeded in acceptable 
yields, but efforts to employ 2-(2-bromophenyl)-1,3-dioxalane, 3-bromobenzonitrile, and 
4-bromobenzophenone were unsuccessful. Substrate II-24b bearing gem-dimethyl 
substitution at C2 was transformed in similar yields and selectivities as in the case of II-
24a, although the use of a substrate bearing diethyl acetal at C2 (II-24c) gave pyrrolidine 
product with lower ee (II-31n). Use of aryl iodide electrophiles (II-31b, II-31d, II-31k) 
gave product yields and enantioselectivities similar to those obtained with aryl bromides, 
but significantly lower reaction times (1 h). Conversely, aryl chlorides were unreactive 
under these conditions, and low yields were obtained with aryl triflate coupling partners 
due to competing base-mediated cleavage of the sulfonate ester. Efforts to employ weak 
bases such as Cs2CO3 or K3PO4 led to low reactivity. Since oxidative addition is more 
challenging for aryl chlorides, attempts at heating the reaction to higher temperatures 
(136 °C) in xylenes to facilitate oxidative addition only led to substrate decomposition.  
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78% yield, 82% ee
(75% yield, 82% ee)d
II-31b
75% yield, 84% ee
(74% yield, 85% ee)e
II-31c
73% yield, 87% ee
II-31d
72% yield, 86% ee
(70% yield, 86% ee)f
OTBS
II-31e
64% yield, 90% ee
II-31f




61% yield, 72% ee
Ph
II-31n
64% yield, 75% ee
II-31i
80% yield, 88% ee
II-31j





80% yield, 82% ee
II-31k
70% yield, 91% ee
(71% yield, 91% ee)g
OMe
II-31m
69% yield, 85% ee
II-31h
66% yield, 80% ee
F
2.5 mol % Pd2(dba)3
7.5 mol % (R)-Siphos-PE







II-24a: R = H
II-24b: R = Me






a Conditions: Reactions were conducted on a 0.2 mmol scale with 1.0 equiv substrate, 2.0 equiv ArBr,
1.0 equiv NaOtBu, 2.5 mol % Pd2(dba)3, 7.5 mol % ligand, toluene (0.2 M), 90 °C, 12-15 h. b
Enantiomeric excess was determined by chiral HPLC analysis. c Isolated yield (average of two or
more experiments). d This reaction was conducted on a 1.0 mmol scale. e 2.0 equiv of 2-iodotoluene

































As shown below in Table 2-11, the best enantioselectivities were obtained with β-
bromostyrene (up to 94% ee) as the electrophilic coupling partner (II-31o, II-31p). 
Alkenyl halides bearing aliphatic chains (II-31r, II-31s) were also effective coupling 
partners for the reaction. Two equivalents of the alkenyl coupling partner were required, 
since dimerization of the alkenyl bromide can be problematic.16 Low yields were 
obtained when low boiling alkenyl bromides such as 1-bromo-propene were employed in 
the reaction, even in excessive quantities.  
Table 2-11. Catalytic Asymmetric Synthesis of 2-(Alkenylmethyl)pyrrolidinesa,b,c 
2.5 mol % Pd2(dba)3
7.5 mol % (R)-Siphos-PE







II-24a: R = H








62% yield, 91% ee
Ph
II-31o
76% yield, 93% ee
II-31p
61% yield, 94% ee
II-31s





70% yield, 93% ee
a Conditions: Reactions were conducted on a 0.2 mmol scale with 1.0 equiv substrate, 2.0 equiv
alkenylBr, 1.0 equiv NaOtBu, 2.5 mol % Pd2(dba)3, 7.5 mol % ligand, toluene (0.2 M), 90 °C, 12-15 h.













 In general, side products were not observed in crude reaction mixtures, and it is 
likely that modest yields result from competing base-mediated substrate decomposition. 
Secondary tert-butyl carbamates have been shown to undergo elimination reactions to 
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afford reactive isocyanates when heated in the presence of NaOtBu.17 When a solution of 
II-24a and NaOtBu in toluene-d8 was heated to 90 °C for about 3 h, 35% decomposition 
of II-24a to the isocyanate was observed.  
 1,1- and 1,2-disubstituted alkenes II-25 and II-26 were examined for the coupling 
of 2-bromonaphthalene (Scheme 2-10). Under the optimized reaction conditions, no 
pyrrolidine product formation was observed. Efforts to employ a combination of weaker 
bases (Cs2CO3, K3PO4), ethereal solvents (dioxane, diglyme) and higher temperatures 
often led to low conversion to pyrrolidine products (II-34 and II-35). Substitution on the 
alkene seems to shut down alkene insertion in the asymmetric carboamination reaction. 
In our studies on intramolecular insertion of alkenes into PdN bonds, we have observed 
that dppf(Pd)(aryl)amido complexes that bear 1,1-disubstituted alkenes undergo slower 
syn-aminopalladation than the corresponding unsubstituted alkene dppf(Pd)(aryl)amido 
complexes.18 
Scheme 2-10. Asymmetric Carboamination of Substituted N-Boc-pent-4-enylamines 
 
 We were also interested in exploring the possibility of achieving catalyst control 
in substrates bearing stereocenters to provide disubstituted products that are hard to 
access with achiral catalysts. In previous studies on diastereoselective synthesis of 
pyrrolidines, the carboamination reaction proceeds in good selectivity for cis-2,5-
disubstituted pyrrolidines and trans-2,3-disubstituted pyrrolidines.9 Our goal was to use 
our Pd/Siphos-PE system and override any inherent substrate control in the alkene 
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insertion step. This would potentially provide access to either pyrrolidine diastereomer 
via substrate-controlled achiral carboamination reaction (cis-2,5- and trans-2,3-
disubstiuted pyrrolidines) or catalyst-controlled asymmetric palladium reaction (trans-2,5 
or cis-2,3-disubstiuted pyrrolidines). We decided to test the feasibility of this idea with 
racemic substrates II-36 and II-37 (Scheme 2-11). If there was any catalyst control, a 
change in diastereoselectivity in favor of the trans-2,5-disubstituted and cis-2,3-
disubstituted product would be observed respectively. Alternatively, a kinetic resolution 
of II-36 or II-37 could also occur. Unfortunately, subjecting racemic substrates II-36 and 
II-37 to the reaction conditions resulted in decomposition of the starting material and no 
product formation, which demonstrates the sensitivity of the Pd/Siphos-PE system to 
subtle changes to the substrate. 





2.5 mol % Pd2(dba)3
7.5 mol % (R)-Siphos-PE






2.5 mol % Pd2(dba)3
7.5 mol % (R)-Siphos-PE




2.7 Total Synthesis of ()-Tylophorine 
In order to illustrate the utility of the enantioselective carboamination reaction and 
establish the absolute configuration of the pyrrolidine products, a short total synthesis of 
()-tylophorine (II-1) was pursued (Scheme 2-12). ()-Tylophorine is a 
phenanthroindolizidine alkaloid that exhibits potent antitumor and antiviral activities,19 
and there has been considerable interest in the development of efficient synthetic routes 
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to tylophorine and other related phenanthroindolizidine alkaloids.20 Our enantioselective 
synthesis of ()-tylophorine employs a route analogous to that developed by Herr for the 
construction of (±)-tylophorine.21 Aryl bromide II-38 was prepared in four steps,21 and 
then coupled with II-24a using our Pd/Siphos-PE system. The coupling of II-24a and 
aryl bromide II-38 proceeded smoothly in 69% yield and 88% ee. Intermediate II-39 was 
converted to ()-tylophorine (II-1) in two steps via deprotection of the Boc protecting 
group followed by treatment with refluxing formalin. The absolute stereochemistry of 
pyrrolidine products II-31a-s were assigned based on analogy to ()-tylophorine (II-1).  

























2 mol % Pd2(dba)3
6 mol % (R)-Siphos-PE
NaOtBu, Toluene, 110 °C
69% yield, 88% ee
II-38
 
2.8 Mechanistic Considerations 
The mechanism of Pd/phosphine catalyzed alkene carboamination reactions is 
believed to involve intramolecular alkene insertion into the PdN bond of an 
intermediate LnPd(Ar)(NRR’) complex (e.g. II-40). Carboncarbon bond-forming 
reductive elimination from II-41 then leads to the formation of pyrrolidine products II-42 
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that result from net suprafacial addition of the aryl and the nitrogen atom across the 
alkene (Scheme 2-13).9a,18 Studies on the reactivity of 
(dppf)Pd(Ar)[N(Ar)(CH2)3CH=CH2 complexes have indicated that the rates of 
aminopalladation and reductive elimination are comparable and aminopalladation is not 
reversible under the stoichiometric conditions.18  
Scheme 2-13. Syn-Aminopalladation Mechanism  
 
 It appears that the absolute stereochemistry of the product is determined during 
the CN bond forming step (II-40 to II-41). However, the Pd/Siphos-PE system is 
different from the bidentate phosphine ligands (e.g., dpe-phos or dppb) used for the 
synthesis of racemic pyrrolidines.9 Thus, we sought to determine if the Pd/Siphos-PE 
system also occurred via syn-aminopalladation. As shown in Scheme 2-14, coupling of 
deuterated substrate II-24d and bromobenzene provided pyrrolidine product II-31t, 
which results from suprafacial addition of the alkene into the PdN and suggests that 
both the asymmetric and nonasymmetric variants of the carboamination reaction proceed 
through similar pathways. The stereochemistry of II-31t was established by conversion to 
known compound II-43.  
Scheme 2-14. Deuterium-Labeling Study 
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 Although the precise structure of the transition state leading to the major 
enantiomer is not clear, our data provides some information about the enantiodetermining 
step. The enantioselectivities obtained in the conversion of II-24a to II-31a did not 
change when ligand:metal ratios were adjusted from 1:1 to 2:1, which suggests a 
monoligated palladium complex is involved in the enantiodetermining step. The poor 
asymmetric induction obtained with chiral bis-phosphines (Table 2-1) may be due to 
dissociation of one arm of the bis-phosphine ligand prior to aminopalladation, which 
would place much of the chiral steric bulk away from the reactive site.22 A related 
hypothesis has previously been invoked to account for the effect of reaction conditions on 
asymmetric induction in enantioselective intramolecular Heck reactions involving chiral 
bis-phosphine BINAP ligands.22  
The high selectivities obtained with these ligands in our carboamination reactions 
may likely arise from steric bulk and chiral elements on both the diol and amine groups. 
Toste and coworkers have reported X-ray structural data on AuCl-(R)-Siphos-PE 
complex II-44.23 As shown in Figure 2-3, these phosphoramidite ligands exhibit a high 
degree of steric bulk around the metal center, which appear to be projected around the 
metal center to a much greater degree than chiral-bis phosphines when bound to a single 
phosphorous atom.24  
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2.9 Summary and Future Directions 
In conclusion, we have developed enantioselective Pd-catalyzed alkene 
carboamination reactions that afford 2-(arylmethyl)- or 2-(alkenylmethylpyrrolidines) in 
good yields and enantioselectivities. This method provides access to an important class of 
nitrogen heterocycles and a new route to enantiomerically enriched 
phenanthroindolizidines. Further studies on the design of more efficient phosphoramidite 
ligand derivatives for these transformations are currently ongoing. We are also interested 
in synthesizing a variety of Pd/phosphoramidite complexes and performing modeling 
studies to gain insight on the structural features of the catalyst system that are responsible 





 All reactions were carried out in flame-dried glassware under an atmosphere of 
nitrogen. Palladium acetate, tris(dibenzylideneacetone)dipalladium (0), allylpalladium 
chloride dimer, and dichlorobis(acetonitrile)palladium (II) were purchased from Strem 
Chemical Co. and used without further purification. (R)-Siphos-PE and all other ligands 
were either purchased from commercial sources (Strem Chemical Co. or Aldrich 
Chemical Co.) and used without further purification, or were synthesized according to 
published procedures.25 All aryl and alkenyl bromides, except for 9-bromo-2,3,6,7-
tetramethoxyphenanthrene (II-38),21 (Z)-β-bromostyrene,26 (Z)-1-bromo-1-decene,27 and 
(E)-1-bromo-1-decene,27 were obtained from commercial sources and were used without 
further purification.  Tert-butyl pent-4-en-1-ylcarbamate (II-24a),9f tert-butyl (2,2-
dimethylpent-4-en-1-yl)carbamate (II-24b),11 (E)-tert-butyl-5-d-pent-4-en-1-ylcarbamate 
(II-24d),9f  tert-butyl (1-phenylpent-4-en-1-yl)carbamate (II-25),9f and tert-butyl (3-
methylpent-4-en-1-yl)carbamate (II-26)9f were prepared according to published 
procedures. Toluene was purified using a GlassContour solvent purification system. 
Yields refer to isolated yields of compounds estimated to be ≥95% pure by 1H NMR, GC 
and/or combustion analysis. The yields reported in the supporting information describe 
the result of a single experiment, whereas yields reported in Table 2-10, Table 2-11, 
Scheme 2-12, and Scheme 2-14 are average yields of two or more experiments. Thus, the 
yields reported in the supporting information may differ from those shown in Table 2-10, 
Table 2-11, Scheme 2-12, and Scheme 2-14.  
 
Experimental Procedures and Compound Characterization Data: 
 
Synthesis of Substrate II-24c 
 
 
2,2-Diethoxypent-4-enenitrile. A flame dried flask was cooled under a stream of 
nitrogen and charged with diisopropylamine (2.4 mL, 17.2 mmol) and THF (60 mL). The 
resulting solution was cooled to –78 ºC, n-BuLi (6.8 mL, 17.2 mmol) was added 
dropwise, and the reaction mixture was stirred for 30 minutes at –78 °C. 
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Diethoxyacetonitrile (2 mL, 14.4 mmol) was added dropwise, the solution was stirred for 
1 hr at –78 °C, then allyl bromide (1.5 mL, 17.2 mmol) was added dropwise and the 
mixture was warmed to rt and stirred for 12 h. The reaction mixture was then cooled to 0 
ºC and quenched with water (10 mL). The mixture was diluted with ether (50 mL), 
transferred to a separatory funnel and the layers were separated. The aqueous layer was 
extracted with ether (2 x 50 mL) and the combined organic layers were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
silica gel chromatography to afford 0.470 g (20%) of the title compound as a pale yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 5.88–5.75 (m, 1 H), 5.30–5.22 (m, 2H), 3.74–3.62 (m, 
4 H), 2.67 (d, J = 6.8 Hz, 2 H), 1.25 (t, J = 6.8 Hz, 6 H); 13C NMR (100 MHz, CDCl3) δ 
129.7, 120.5, 116.0, 98.8, 59.9, 41.5, 14.8; IR (film) 1683, 1054 cm-1; MS (ESI): 
170.1172 (170.1176 calcd for C9H15NO2, M + H+). 
 
 
tert-Butyl (2,2-diethoxypent-4-en-1-yl)carbamate (II-24c). A flame dried flask was 
cooled under a stream of nitrogen and charged with a solution of LiAlH4 in ether (4.2 
mL, 4.2 mmol, 1 M). The solution was cooled to 0 ºC and a solution of 2,2-diethoxypent-
4-enenitrile (0.470 g, 2.8 mmol) in Et2O (10 mL) was added dropwise. The resulting 
solution was stirred overnight at room temperature, then was diluted with 10 mL of ether, 
cooled to 0 ºC. Water (0.16 mL) was added dropwise, followed by a solution of 10 M 
NaOH (0.16 mL) and additional water (0.48 mL). A white precipitate formed and 
adhered to the walls of the reaction vessel. The solution was decanted, and the precipitate 
was washed with ether (10 mL). The combined organic layers were filtered through 
celite, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The 
crude product was dissolved in methylene chloride (15 mL) and solid Boc2O (0.676 g, 
3.1 mmol) was added. The resulting mixture was stirred at rt for 12 h, then the solution 
was concentrated in vacuo. The crude product was purified by flash chromatography on 
silica gel to afford 500 mg (65%) of the title compound as a clear viscous oil. 1H NMR 
(400 MHz, CDCl3) δ 5.88–5.71 (m, 1 H), 5.14–5.06 (m, 2H), 4.58 (s, 1 H), 3.55–3.43 (m, 
4 H), 3.28 (d, J = 6.0 Hz, 2 H), 2.40 (d, J = 7.2 Hz, 2 H), 1.44 (s, 9 H), 1.17 (t, J = 6.8 Hz, 
6 H); 13C NMR (100 MHz, CDCl3) δ 155.5, 132.6, 118.3, 101.1, 79.2, 55.9, 42.4, 38.1, 
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28.4, 15.3; IR (film) 3363, 1718, 1507 cm-1; MS (ESI): 296.1839 (296.1838 calcd for 
C14H27NO4, M + Na+). 
 
Synthesis and Characterization Data for Pyrrolidine Products 
General Procedure: Synthesis of Pyrrolidines via Pd-Catalyzed Carboamination.  
A flame-dried Schlenk tube was cooled under a stream of nitrogen and charged 
with charged with Pd2(dba)3 (2.5 mol % complex, 5 mol % Pd), (R)-Siphos-PE (7.5 mol 
%) and NaOtBu (1.0-2.0 equiv). The tube was purged with nitrogen, then a solution of 
the amine substrate (0.2 mmol) and aryl halide (2.0 equiv) or alkenyl halide (2.0 equiv) in 
toluene (0.2 M) was added via syringe (aryl bromides that were solids at room 
temperature were added following the addition of NaOtBu). The mixture was heated to 
90 °C with stirring until the starting material had been consumed as judged by GC or 1H 
NMR analysis. The reaction mixture was cooled to room temperature, quenched with 
saturated aqueous NH4Cl (2 ml) and diluted with EtOAc (5 ml). The layers were 
separated and the aqueous layer was extracted with EtOAc (2 x 5 ml). The combined 
organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by flash chromatography on silica gel.  
 
 
(R)-(–)-tert-Butyl 2-(napthalen-2-ylmethyl)pyrrolidine-1-carboxylate (II-31a). The 
general procedure was employed for the coupling of 2-bromonaphthalene (83 mg, 0.4 
mmol) with tert-butyl pent-4-en-1-ylcarbamate II-24a (37 mg, 0.2 mmol) and NaOtBu 
(19 mg, 0.2 mmol). This procedure afforded 50 mg (80%) of the title compound as a pale 
yellow oil. Spectroscopic data were consistent with those previously reported in the 
literature.9e [α]23D –3.9 (c 1.0, CH2Cl2). The enantiopurity was determined to be 82% ee 
by chiral HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 




(R)-(–)-tert-Butyl 2-(-2-methylbenzyl)pyrrolidine-1-carboxylate (II-31b). The general 
procedure was employed for the coupling of 2-bromotoluene (69 mg, 0.4 mmol) with 
tert-butyl pent-4-en-1-ylcarbamate II-24a (37 mg, 0.20 mmol) and NaOtBu (19 mg, 0.2 
mmol). This procedure afforded 44 mg (80%) of the title compound as a pale yellow oil. 
Spectroscopic data were consistent with those previously reported in the literature.9e 
[α]23D –22.0 (c 1.0, CH2Cl2). The enantiopurity was determined to be 84% ee by chiral 
HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 mL/min, λ = 
254 nm, RT = 9.7 and 10.8 min). When 2-iodotoluene (87 mg, 0.4 mmol) was employed 




(R)-(–)-tert-Butyl 2-(3-methoxybenzyl)pyrrolidine-1-carboxylate (II-31c). The general 
procedure was employed for the coupling of 3-bromoanisole (75 mg, 0.4 mmol) with 
tert-butyl pent-4-en-1-ylcarbamate II-24a (37 mg, 0.2 mmol) and NaOtBu (19 mg, 0.2 
mmol). This procedure afforded 43.7 mg (75%) of the title compound as a pale yellow 
oil. [α]23D –5.2 (c 1.0, CH2Cl2); 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.05–6.97 (m, 
1 H), 6.77 (s, 1 H), 6.74 (d, J = 7.6 Hz, 1 H), 6.63 (dd, J = 2.0, 8.4 Hz, 1 H), 4.02–3.95 
(m, 1 H), 3.45 (s, 3 H) 3.32–3.22 (m, 1 H), 3.20–3.04 (m, 2 H), 2.51 (dd, J = 9.2, 12.8 
Hz, 1 H), 1.53–1.30 (m, 13 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 160.6, 154.2, 
141.3, 129.3, 122.2, 115.9, 112.2, 78.6, 59.0, 54.8, 46.8, 40.8, 29.9, 28.7, 23.4; IR (film) 
1691, 1395 cm–1; MS (ESI) 314.1731 (314.1732 calcd for C17H25NO3, M + Na+). The 
enantiopurity was determined to be 87% ee by chiral HPLC analysis (R,R-Whelk-O 1, 25 




(R)-(+)-tert-Butyl-2-(4-methoxybenzyl)pyrrolidine-1-carboxylate (II-31d). The 
general procedure was employed for the coupling of 4-bromoanisole (75 mg, 0.4 mmol) 
with tert-butyl pent-4-en-1-ylcarbamate II-24a (37 mg, 0.2 mmol) and NaOtBu (19 mg, 
0.2 mmol) using Pd2(dba)3 (4.6 mg, 0.005 mmol) as the palladium source. This procedure 
afforded 39 mg (67%) of the title compound as a pale yellow oil. [α]23D +4.8 (c 1.0, 
CH2Cl2). 1H NMR (400 MHz, C6D5CD3, 100 °C)  δ 7.03–6.97 (m, 2 H), 6.74–6.68 (m, 2 
H), 4.00–3.92 (m, 1 H), 3.42 (s, 3 H), 3.34–3.22 (m, 1 H), 3.30–3.10 (m, 1 H), 3.03 (dd, J 
= 2.8, 13.2 Hz, 1 H), 2.50 (dd, J = 8.8, 13.2 Hz, 1 H), 1.54–1.32 (m, 13 H); 13C NMR 
(100 MHz, C6D5CD3, 100 °C) δ 159.1, 154.2, 131.9, 129.0, 114.5, 78.5, 59.2, 54.9, 46.9, 
39.8, 29.9, 28.7, 20.4; IR (film) 1691, 1392 cm–1; MS (ESI) 314.1734 (314.1732 calcd for 
C17H25NO3, M + Na+). The enantiopurity was determined to be 86% ee by chiral HPLC 
analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 mL/min, λ = 231 nm, 
RT = 25.8 and 27.5 min). When 4-iodoanisole was employed as the coupling partner, this 




(II-31e). The general procedure was employed for the coupling of (4-bromophenoxy)-
tert-butyldimethylsilane (115 mg, 0.4 mmol) with tert-butyl pent-4-en-1-ylcarbamate II-
24a (37 mg, 0.2 mmol) and NaOtBu (19 mg, 0.2 mmol). This procedure afforded 48 mg 
(61%) of the title compound as a pale yellow oil. [α]23D +8.9 (c 1.0, CH2Cl2). 1H NMR 
(400 MHz, C6D5CD3, 100 °C) δ 6.98 (d, J = 8.4 Hz, 2 H), 6.73 (d, J = 8.4 Hz, 2 H), 
4.02–3.91 (m, 1 H), 3.35–3.23 (m, 1 H), 3.20–3.10 (m, 1 H), 3.01 (d, J = 13.2 Hz, 1 H), 
2.50 (dd, J = 8.8, 13.2 Hz, 1 H), 1.47–1.31 (m, 13 H), 0.96 (s, 9 H), 0.12 (s, 6 H); 13C 
NMR (100 MHz, C6D5CD3, 100 °C) δ 154.6, 132.6, 130.6, 129.0, 120.2, 78.5, 59.1, 36.8, 
39.9, 29.9, 28.7, 23.9, 23.4, 18.4, –4.4; IR (film) 1696, 1653, 1394, 1256; MS (ESI) 
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414.2446 (414.2440 calcd for C22H37NO3Si, M + Na+). The enantiopurity was determined 
to be 90% ee by chiral HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% 




carboxylate (II-31f). The general procedure was employed for the coupling of 4-(tert-
butyldimethylsilyl)-hydroxymethylbromobenzene (121 mg, 0.4 mmol) with tert-butyl 
pent-4-en-1-ylcarbamate II-24a (37 mg, 0.2 mmol) and NaOtBu (19 mg, 0.2 mmol). This 
procedure afforded 50 mg (62%) of the title compound as a pale yellow oil. [α]23D +0.8 (c 
1.0, CH2Cl2). 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.19 (d, J = 7.2 Hz, 2 H), 7.10–
7.05 (m, 2 H), 4.61 (s, 2 H), 4.01–3.94 (m, 1 H), 3.28 (dd, J = 8.8, 17.6 Hz, 1 H), 3.18–
3.05 (m, 2 H), 2.52 (dd, J = 8.8, 12.4 Hz, 1 H), 1.48–1.30 (m, 13 H), 0.94 (s, 9 H), 0.04 
(s, 6 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 154.2, 139.7, 138.5, 129.6, 126.7, 
78.6, 65.4, 59.1, 46.8, 40.4, 29.9, 28.7, 26.1, 23.4, 18.5, –5.2; IR (film) 1696, 1394 cm-1; 
MS (ESI) 428.2602 (428.2597 calcd for C23H39NO3Si, M + Na+). The enantiopurity was 
determined to be 85% ee by chiral HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% 




31g). The general procedure was employed for the coupling of tert-butyl-4-
bromobenzoate (103 mg, 0.4 mmol) with tert-butyl pent-4-en-1-ylcarbamate II-24a (37 
mg, 0.2 mmol) and NaOtBu (19 mg, 0.2 mmol). This procedure afforded 46 mg (64%) of 
the title compound as a pale yellow oil. [α]23D +6.8 (c 1.0, CH2Cl2). 1H NMR (400 MHz, 
C6D5CD3, 100 °C) δ 7.96 (d, J  = 8.0 Hz, 2 H), 7.07 (d, J = 8.0 Hz, 2 H), 3.98–3.89 (m, 1 
H), 3.30–3.21 (m, 1 H), 3.14–3.04 (m, 2 H), 2.51 (dd, J = 9.2, 12.4 Hz, 1 H), 1.48 (s, 9 
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H), 1.46 (s, 9 H), 1.42–1.27 (m, 4 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 165.5, 
154.2, 144.4, 131.2, 129.9, 129.5, 80.2, 78.7, 58.8, 46.8, 40.6, 29.9, 28.7, 28.3, 23.4; IR 
(film) 1713, 1696, 1394 cm-1; MS (ESI) 384.2153 (384.2151 calcd for C21H31NO4, M + 
Na+). The enantiopurity was determined to be 72% ee by chiral HPLC analysis (R,R-







(R)-(+)-tert-Butyl 2-(4-fluorobenzyl)pyrrolidine-1-carboxylate (II-31h). The general 
procedure was employed for the coupling of 1-bromo-4-fluorobenzene (70 mg, 0.4 
mmol) with tert-butyl pent-4-en-1-ylcarbamate II-24a (37 mg, 0.2 mmol) and NaOtBu 
(19 mg, 0.2 mmol). This procedure afforded 37 mg (66%) of the title compound as a pale 
yellow oil. [α]23D +4.1 (c 1.0, CH2Cl2). 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 6.97–
6.88 (m, 2 H), 6.79–6.72 (m, 2 H), 3.92–3.84 (m, 1 H), 3.30–3.21 (m, 1 H), 3.14–3.06 
(m, 1 H), 2.97 (dd, J = 2.6, 13.2 Hz, 1 H), 2.48–2.40 (dd, J = 8.4, 12.8 Hz, 1 H), 1.45 (s, 
9 H), 1.40–1.30 (m, 4 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 162.2 (d, J = 243 
Hz), 154.2, 135.4, 131.0 (d, J = 7.4 Hz), 115.2 (d, J = 20 Hz), 78.7, 58.9, 46.8, 39.8, 
29.9, 28.7, 23.4; IR (film) 1692, 1394 cm–1; MS (ESI) 302.1534 (302.1532 calcd for 
C16H22FNO2, M + Na+). The enantiopurity was determined to be 80% ee by chiral HPLC 
analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 mL/min, λ= 254 nm, 




(II-3i). The general procedure was employed for the coupling of 2-bromonaphthalene (83 
mg, 0.4 mmol) with tert-butyl (2,2-dimethylpent-4-en-1-yl)carbamate II-24b (43 mg, 0.2 
mmol) and NaOtBu (19 mg, 0.2 mmol). This procedure afforded 55 mg (81%) of the title 
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compound as a pale yellow oil. [α]23D +31.7 (c 1.0, CH2Cl2). 1H NMR (400 MHz, 
C6D5CD3, 100 °C) δ 7.62–6.53 (m, 4 H), 7.28 (d, J = 8.8 Hz, 1 H), 7.25–7.16 (m, 2 H), 
4.16 (dq, J = 4.8, 8.0 Hz, 1 H), 3.50 (dd, J = 2.4, 12.8 Hz, 1 H), 3.38 (d, J = 10.4 Hz, 1 
H), 2.83–2.75 (m, 2 H), 1.54–1.33 (m, 11 H), 0.79 (s, 3 H), 0.76 (s, 3H); 13C NMR (100 
MHz, C6D5CD3, 100 °C) δ 154.9, 137.1, 134.4, 132.9, 128.4, 128.2, 128.1, 127.9, 127.8, 
125.9, 125.3, 78.7, 60.1, 59.0, 45.8, 41.6, 37.1, 28.7, 26.4, 26.1; IR (film) 1689, 1164 cm–
1; MS (ESI) 362.2093 (362.2096 calcd for C22H29NO2, M + Na+). The enantiopurity was 
determined to be 88% ee by chiral HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% 




carboxylate (II-31j). The general procedure was employed for the coupling of 4-bromo-
N,N-dimethylaniline (80 mg, 0.4 mmol) with tert-butyl (2,2-dimethylpent-4-en-1-
yl)carbamate II-24b (43 mg, 0.2 mmol) and NaOtBu (19 mg, 0.2 mmol). This procedure 
afforded 44.6 mg (67%) of the title compound as a pale yellow oil. [α]23D +49.1 (c 1.0, 
CH2Cl2); 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.05–7.02 (m, 1 H), 6.96–6.94 (m, 1 
H), 6.57–6.52 (m, 2 H), 4.09–4.00 (m, 1 H), 3.37 (d, J = 10.4 Hz, 1 H), 3.26 (dd, J = 2.4, 
13.2 Hz, 1 H), 2.77 (d, J = 10.8 Hz, 1 H), 2.66–2.56 (m, 7 H), 1.49–1.33 (m, 11 H), 0.80 
(s, 3 H), 0.76 (s, 3 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 154.9, 149.9, 130.5, 
113.5, 78.5, 60.1, 59.3, 45.8, 40.4, 37.0, 30.6, 28.8, 26.6, 26.2 (1 peak is missing due to 
incidental equivalence); IR (film) 1691, 1163 cm–1;  MS (ESI) 333.2546 (333.2542 calcd 
for C20H32N2O2, M + Na+). The enantiopurity was determined to be 92% ee by chiral 
HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 mL/min, λ = 





carboxylate (II-31k). The general procedure was employed for the coupling of 3-
bromobenzotrifluoride (90 mg, 0.4 mmol) with tert-butyl (2,2-dimethylpent-4-en-1-
yl)carbamate II-24b (43 mg, 0.2 mmol) and NaOtBu (19 mg, 0.2 mmol). This procedure 
afforded 50.2 mg (70%) of the title compound as a pale yellow oil [α]23D +25.2 (c 1.0, 
CH2Cl2); 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.45 (s, 1 H), 7.27 (d, J = 7.6 Hz, 1 
H), 7.15 (d, J = 7.6 Hz, 1 H), 7.04–6.97 (m, 1 H), 3.98 (m, 1 H), 3.31 (d, J = 10.4 Hz, 1 
H), 3.18 (dd, J = 2.8, 12.8 Hz, 1 H), 2.70–2.62 (m, 2 H), 1.46 (s, 9 H), 1.42–1.32 (m, 1 
H), 1.21–1.14 (m, 1 H), 0.75 (s, 3 H), 0.72 (s, 3 H); 13C NMR (100 MHz, C6D5CD3, 100 
°C) δ 154.8, 140.7, 133.1, 131.2 (q, J = 31.7 Hz), 126.6, 126.3, 125.0 (q, J = 270 Hz), 
123.2, 78.9, 60.0, 58.6, 45.4, 40.8, 37.1, 28.6, 26.3, 25.9 (one peak is missing due to 
incidental equivalence); IR (film) 1695, 1163 cm–1; MS (ESI) 380.1827 (380.1813 calcd 
for C19H26F3NO2, M + Na+). The enantiopurity was determined to be 91% ee by chiral 
HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 0.5 mL/min, λ = 
254 nm, RT = 14.6 and 15.9 min). When 3-iodobenzotrifluoride was employed as the 




31l). The general procedure was employed for the coupling of 1-bromo-4-tert-
butylbenzene (85 mg, 0.4 mmol) with tert-butyl (2,2-dimethylpent-4-en-1-yl)carbamate 
II-24b (43 mg, 0.2 mmol) using NaOtBu (19 mg, 0.2 mmol). This procedure afforded 48 
mg (70%) of the title compound. [α]23D +25.7 (c 1.0, CH2Cl2). 1H NMR (400 MHz, 
C6D5CD3, 100 °C) δ 7.22 (d, J = 8.0 Hz, 2 H), 7.10 (d, J = 8.4 Hz, 2 H), 4.12–4.02 (m, 1 
H), 3.42–3.30 (m, 2 H), 2.79 (d, J = 10.8 Hz, 1 H), 2.62 (dd, J = 8.8, 12.8 Hz, 1 H), 1.51–
1.40 (m, 10 H), 1.36–1.21 (m, 10 H), 0.80 (s, 3 H), 0.75 (s, 3 H); 13C NMR (100 MHz, 
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C6D5CD3, 100 °C) δ 154.9, 149.1, 136.5, 129.6, 125.3, 78.6, 60.1, 59.1, 45.9, 41.0, 37.1, 
34.4, 31.5, 28.7, 26.5, 26.2; IR (film) 1694, 1394 cm–1; MS (ESI) 368.2557 (368.2560 
calcd for C22H35NO2, M + Na+). The enantiopurity was determined to be 82% ee by chiral 
HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 mL/min, λ = 




31m). The general procedure was employed for the coupling of 4-bromoanisole (75 mg, 
0.4 mmol) with tert-butyl (2,2-dimethylpent-4-en-1-yl)carbamate II-24b (43 mg, 0.2 
mmol) using NaOtBu (19 mg, 0.2 mmol). This procedure afforded 45 mg (70%) of the 
title compound as a pale yellow oil. [α]23D +39.1 (c 1.0, CH2Cl2); 1H NMR (400 MHz, 
C6D5CD3, 100 °C) δ 7.05–6.97 (m, 2 H), 6.72 (d, J = 8.8 Hz, 2 H), 4.08–3.99 (m, 1 H), 
3.45–3.35 (m, 4 H), 3.26  (dd, J = 2.8, 13.2 Hz, 1 H) 2.76 (d, J = 10.8 Hz, 1 H), 2.63 (dd, 
J = 9.2, 13.2 Hz, 1 H), 1.53–1.42 (m, 10 H), 1.36–1.29 (s, 1 H), 0.81 (s, 3 H), 0.77 (s, 3 
H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 159.1, 154.9, 131.6, 130.7, 114.4, 78.6, 
60.1, 59.2, 54.9, 45.7, 40.4, 37.0, 28.7, 26.5, 26.4; IR (film) 1691, 1164 cm–1; MS (ESI) 
342.2038 (342.2045 calcd for C19H29NO3, M + Na+). The enantiopurity was determined 
to be 85% ee by HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 









carboxylate (II-31n). The general procedure was employed for the coupling of 4-
bromobiphenyl (70 mg, 0.4 mmol) with tert-butyl (2,2-diethoxypent-4-en-1-yl)carbamate 
II-24c (55 mg, 0.2 mmol) and NaOtBu (19 mg, 0.2 mmol). This procedure afforded 55 
mg (65%) of the title compound as a pale yellow oil. [α]23D +6.0 (c 1.0, CH2Cl2). 1H 
NMR (400 MHz, CDCl3, 25 °C) δ 7.44–7.36 (m, 4 H), 7.23–7.16 (m, 4 H), 7.11–7.08 (m, 
1 H), 4.23–4.15 (m, 1 H), 3.81 (d, J = 11.6 Hz, 1 H), 3.40–3.23 (m, 6 H), 2.80 (dd, J = 
9.6, 12.8 Hz, 1 H), 1.97–1.90 (m, 1 H), 1.86–1.79 (m, 1 H), 1.47 (s, 9 H), 1.03 (td, J = 
7.2, 16.4 Hz, 6 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 154.6, 141.7, 139.8, 138.7, 
130.1, 128.8, 127.4, 127.2, 127.1, 107.0, 79.0, 58.5, 57.9, 57.5, 53.6, 40.5, 30.9, 28.7, 
15.4, 15.3; IR (film) 1696, 1394 cm-1; MS (ESI) 448.2462 (448.2464 calcd for 
C26H35NO4, M + Na+). The enantiopurity was determined to be 75% ee by chiral HPLC 
analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 mL/min, λ = 231 nm, 
RT = 17.7 and 20.7 min). 
 
 
(R,E)-(+)-tert-Butyl 2-cinamylpyrrolidine-1-carboxylate (II-31o). The general 
procedure was employed using for the coupling of (E)-β-bromostyrene (73 mg, 0.4 
mmol) with tert-butyl pent-4-en-1-ylcarbamate II-24a (37 mg, 0.2 mmol) and NaOtBu 
(39 mg, 0.4 mmol) using Pd2(dba)3 (4.6 mg, 0.0015 mmol) as the palladium source. This 
procedure afforded 46.8 mg (81%) of the title compound as a pale yellow oil. 
Spectroscopic data were consistent with those previously reported in the literature.9e 
[α]23D +38.2 (c 1.0, CH2Cl2). The enantiopurity was determined to be 93% ee by chiral 
HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 mL/min, λ = 




(R,Z)-(+)-tert-Butyl 2-(3-phenylallyl)pyrrolidine-1-carboxylate (II-31p). The general 
procedure was employed for the coupling of (Z)-β-bromostyrene (73 mg, 0.4 mmol) with 
tert-butyl pent-4-en-1-ylcarbamate II-24a (37 mg, 0.2 mmol) and NaOtBu (39 mg, 0.4 
mmol) using Pd2(dba)3 (4.6 mg, 0.005 mmol) as the palladium source. This procedure 
afforded 36 mg (63%) of the title compound as a pale yellow oil. [α]23D +55.3 (c 1.0, 
CH2Cl2). 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.21 (d, J = 8.0 Hz, 2 H), 7.13 (t, J = 
7.6 Hz, 2 H), 7.01 (d, J = 7.2 Hz, 1 H), 6.42 (d, J = 12.0 Hz, 1 H), 5.55 (td, J = 7.6, 11.6 
Hz, 1 H), 3.84–3.79 (m, 1 H), 3.34–3.24 (m, 1 H), 3.18–3.09 (m, 1 H), 2.86–2.76 (m, 1 
H), 2.38 (td, J = 7.6, 14.8 Hz, 1 H), 1.62–1.32 (m, 13 H); 13C NMR (125 MHz, C6D5CD3, 
100 °C) δ 154.3, 138.2, 131.2, 129.1, 128.3, 128.2, 126.7, 78.5, 57.6, 46.8, 33.7, 30.5, 
28.6, 23.6; IR (film) 1692, 1392, 1170 cm–1; MS (ESI) 310.1784 (310.1783 calcd for 
C18H25NO2, M + Na+). The enantiopurity was determined to be 94% ee by chiral HPLC 
analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 mL/min, λ = 231 nm, 
RT = 7.0 and 8.9 min). 
 
 
(S,E)-(+)-tert-Butyl 2-cinamyl-4,4-dimethylpyrrolidine-1-carboxylate (II-31q). The 
general procedure was employed for the coupling of (E)-β-bromostyrene (73 mg, 0.4 
mmol) with tert-butyl (2,2-dimethylpent-4-en-1-yl)carbamate II-24b (43 mg, 0.2 mmol) 
and NaOtBu (39 mg, 0.4 mmol). This procedure afforded 45 mg (72%) of the title 
compound as a pale yellow oil. [α]23D +63.5 (c 1.0, CH2Cl2); 1H NMR (400 MHz, 
C6D5CD3, 100 °C) δ 7.20 (d, J = 7.6 Hz, 2 H), 7.12–7.06 (m, 2 H), 7.02–6.96 (m, 1 H), 
6.38 (d, J = 15.6 Hz, 1 H), 6.12–6.03 (m, 1 H), 3.93 (dq, J = 3.6, 8.0 Hz, 1 H), 3.41 (d, J 
= 10.0 Hz, 1 H), 2.88–2.75 (m, 2 H), 2.44–2.35 (m, 1 H), 1.62–1.54 (m, 1 H), 1.46 (s, 9 
H), 1.37–1.29 (m, 1 H), 0.85 (s, 3H), 0.82 (s, 3H); 13C NMR (100 MHz, C6D5CD3, 100 
°C) δ 154.8, 138.5, 133.0, 128.6, 127.1, 127.0, 126.5, 78.6, 60.2, 57.5, 45.9, 38.8, 37.2, 
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28.7, 26.5, 26.1; IR (film) 1692, 1167 cm–1; MS (ESI) 338.2086 (338.2091 calcd for 
C20H29NO2, M + Na+). The enantiopurity was determined to be 93% ee by chiral HPLC 
analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 mL/min, λ = 231 nm, 
RT = 9.3 and 11.2 min). 
 
 
(R,Z)-(+)-tert-Butyl 2-(undec-2-en-1-yl)pyrrolidine-1-carboxylate (II-31r). The 
general procedure was employed for the coupling of (Z)-1-bromo-1-decene (88 mg, 0.4 
mmol) with tert-butyl pent-4-en-1-ylcarbamate II-24a (37 mg, 0.2 mmol) and NaOtBu 
(39 mg, 0.4 mmol). This procedure afforded 40 mg (62%) of the title compound as a pale 
yellow oil. [α]23D +32.3 (c 1.0, CH2Cl2);  1H NMR (400 MHz, C6D5CD3, 100 ºC) δ 5.50–
5.41 (m, 1 H), 5.40–5.31 (m, 1 H), 3.85–3.77 (m, 1 H), 3.38–3.29 (m, 1 H), 3.26–3.18 
(m, 1 H), 2.63–2.53 (m, 1 H), 2.20–2.04 (m, 2 H), 1.75–1.23 (m, 26 H), 0.83 (t, J = 6.8 
Hz, 3 H); 13C NMR (125 MHz, C6D5CD3, 100 °C) 154.2, 132.3, 126.2, 78.4, 57.7, 46.9, 
32.5, 32.2, 30.3, 30.1, 29.9, 29.7, 29.6, 28.7, 27.8, 23.7, 22.9, 13.9; IR (film) 1697, 1393; 
MS (ESI) 346.2726 (346.2722 calcd for C20H37NO2, M + Na+).  The enantiopurity was 




(R,Z)-(+)-1-Tosyl-2-(undec-2-en-1-yl)pyrrolidine (S1). The conversion of (R,Z)-(+)-
tert-butyl 2-(undec-2-en-1-yl)pyrrolidine-1-carboxylate (37 mg, 0.11 mmol) to the title 
compound was accomplished using a procedure analogous to that described above for the 
preparation of S1. This procedure afforded 24.8 mg (60%) of the title compound as a pale 
yellow oil. [α]23D +78.2 (c 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 8.0 
Hz, 2 H), 7.30 (d, J = 8.0 Hz, 2 H), 5.53–5.44 (m, 1 H), 5.39–5.29 (m, 1 H), 3.65–3.57 
(m, 1 H), 3.45–3.37 (m, 1 H), 3.20–3.12 (m, 1 H), 2.64–2.56 (m, 1 H), 2.42 (s, 3 H), 
2.31–2.21 (m, 1 H), 2.05 (q, J = 6.8 Hz, 2 H), 1.84–1.74 (m, 1 H), 1.63–1.44 (m, 3 H), 
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1.38–1.23 (m, 12 H), 0.88 (t, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 143.1, 
134.9, 132.9, 129.5, 127.5, 124.9, 60.3, 49.1, 34.1, 31.9, 30.2, 29.6, 29.5, 29.3, 29.2, 27.5, 
23.9, 22.6, 21.5, 14.1; IR (film) 1652, 1348, 1160 cm-1; MS (ESI) 400.2290 (400.2286 
calcd for C22H35NO2S, M + Na+). The enantiopurity was determined to be 91% ee by 
chiral HPLC analysis (Chiralpak AD-H, 0.46 cm x 25 cm, 1% iPrOH/hexanes, 1 mL/min, 
λ = 254 nm, RT = 10.3 and 11.5 min). 
 
 
(R,E)-(+)-tert-Butyl 2-(undec-2-en-1-yl)pyrrolidine-1-carboxylate (II-31s). The 
general procedure was employed for the coupling of (E)-1-bromo-1-decene (88 mg, 0.4 
mmol) with tert-butyl pent-4-en-1-ylcarbamate II-24a (37 mg, 0.2 mmol) and NaOtBu 
(39 mg, 0.4 mmol). This procedure afforded 39 mg (60%) of the title compound as a pale 
oil. [α]23D +22.1 (c 1.0, CH2Cl2). 1H NMR (400 MHz, C6D5CD3, 100 ºC) δ 5.47–5.30 (m, 
2 H), 3.82–3.73 (m, 1 H), 3.36–3.27 (m, 1 H), 3.22–3.14 (m, 1 H), 2.49–2.41 (m, 1 H), 
1.96 (q, J = 6.8 Hz, 2 H), 1.65–1.21 (m, 26 H), 0.86, (t, J = 6.8 Hz, 3 H); 13C NMR (100 
MHz, C6D5CD3, 100 ºC) δ 154.2, 133.2, 127.1, 78.3, 57.6, 46.8, 37.9, 33.0, 32.2, 30.2, 
29.9, 29.8, 29.6, 29.5, 28.7, 23.6, 22.9, 13.9; IR (film) 1695, 1394 cm-1; MS (ESI) 
346.2717 (346.2722 calcd for C20H37NO2, M + Na+). The enantiopurity was determined 
to be 82% ee by conversion to N-tosyl derivative S2 followed by chiral HPLC analysis.  
 
 
(R,E)-(+)-1-Tosyl-2-(undec-2-en-1-yl)pyrrolidine (S2). A flame dried flask was 
charged with (R,E)-(+)-tert-butyl 2-(undec-2-en-1-yl)pyrrolidine-1-carboxylate (34 mg, 
0.11 mmol) and methylene chloride (1 mL). Trifluoroacetic acid (0.1 mL, 1.3 mmol) was 
added dropwise and the reaction was monitored by TLC analysis. Upon consumption of 
starting material, the solution was concentrated in vacuo. Benzene (5 mL) was added, and 
the resulting was concentrated to facilitate removal of trifluoroacetic acid. This procedure 
was repeated two additional times with 5 mL portions of benzene. The resulting crude 
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product was dissolved in ether (1 mL), and tosyl chloride (32 mg, 0.17 mmol) and 
triethylamine (77 μL, 0.55 mmol) were added. The resulting mixture was stirred at rt for 
ca 12 h, then additional ether (5 mL) was added and the mixture was washed with 
NaHCO3 and extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried 
over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica 
gel chromatography to afford 23 mg (55%) of the title compound as a pale oil. [α]23D 
+72.6. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.0 Hz, 2 H), 7.29 (d, J = 8.0 Hz, 2 H), 
5.51–5.42 (m, 1 H), 5.38–5.30 (m, 1 H), 3.63–3.56 (m, 1 H), 3.40–3.33 (m, 1 H), 3.18–
3.10 (m, 1 H), 2.54–2.47 (m, 1 H), 2.41 (s, 3 H), 2.26–2.16 (m, 1 H), 1.97 (q, J = 6.8 Hz, 
2 H), 1.80–1.69 (m, 1 H), 1.66–1.42 (m, 3 H), 1.38–1.20 (m, 12 H), 0.86 (t, J = 6.8 Hz, 3 
H); 13C NMR (100 MHz, CDCl3) δ 143.1, 134.8, 133.9, 129.5, 127.4, 125.6, 60.1, 49.1, 
39.5, 32.6, 31.8, 29.8, 29.4, 29.3, 29.2, 29.1, 23.9, 22.6, 21.4, 14.0; IR (film) 1348, 1160 
cm-1; MS (ESI) 400.2283 (400.2286 calcd for C22H35NO2S). The enantiopurity was 
determined to be 82% ee by chiral HPLC analysis (Chiralpak AD-H, 0.46 cm x 25 cm, 










carboxylate (II-39).21 The general procedure was employed for the coupling of 9-bromo-
2,3,6,7-tetramethoxyphenanthrene II-38 (38 mg, 0.1 mmol) with tert-butyl pent-4-en-1-
ylcarbamate II-24a (24 mg, 0.13 mmol). This procedure afforded 30 mg (62%) of the 
title compound as an off-white solid. mp: 92–95 ˚C; [α]23D –74.0 (c 0.1, CH2Cl2); 1H 
NMR (400 MHz, CDCl3, 25 °C) δ 8.30 (s, 1 H), 7.81 (s, 1 H), 7.78 (s, 1 H), 7.36 (s, 1 H), 
7.17 (s, 1 H), 4.30–4.19 (m, 4 H), 4.12 (s, 3 H), 4.11 (s, 3 H), 4.02 (s, 3 H), 3.92 (d, J = 
5.4 Hz, 1 H), 3.52–3.45 (m, 1 H), 3.36–3.29 (m, 1 H), 2.59 (t, J = 11.9 Hz, 1 H), 2.05–
1.98 (m, 1 H), 1.88–1.78 (m, 2 H), 1.75–1.63 (m, 1 H), 1.51 (s, 9 H). The enantiopurity 
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was determined to be 88% ee by transforming the title compound to (R)-(–)-tylophorine 









(R)-(–)-Tylophorine (II-I). The title compound was synthesized following the procedure 
reported by Herr. A mixture of (R)-(–)-tert-butyl-2-[(2,3,6,7-tetramethoxyphenanthrene-
9-yl)methyl]pyrrolidine-1-carboxylate II-39 (33 mg, 0.07 mmol) in a solution of HCl in 
methanol (2.0 mL, 1.25 M, 2.5 mmol) was stirred at room temperature under nitrogen for 
4 h. at A 37% solution of formalin (2.0 mL, 24.6 mmol) was added and the mixture was 
refluxed overnight. The reaction mixture was cooled to room temperature and diluted 
with water (5 mL) and aqueous 2 M NaOH (10 mL). The resulting mixture was extracted 
with methylene chloride (3 x 10 mL), then the organic layers were combined, dried over 
anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by 
flash chromatography on silica gel to provide (R)-(–)-tylophorine as a light yellow solid 
(27 mg, 99 % yield), mp: 272–274 ˚C (lit. mp: 273 – 275 ˚C). [α]23D –62.0 (c 0.10, 
CHCl3) (lit. [α]30D –76.0 (c 0.10, CHCl3).28 1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 2 
Hz, 2 H), 7.32 (s, 1 H), 7.17 (s, 1 H), 4.63 (d, J = 14.4 Hz, 1 H), 4.11 (s, 6 H), 4.05 (s, 6 
H), 3.67 (d, J = 14.8 Hz, 1 H), 3.52–3.45 (m, 1 H), 3.41–3.34 (m, 1 H), 2.96–2.87 (m, 1 
H), 2.55–2.42 (m, 2 H), 2.30–2.20 (m, 1 H), 2.11–1.99 (m, 1 H), 1.97–1.90 (m, 1 H), 
1.84–1.73 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 148.7, 148.5, 148.4, 126.3, 125.8, 
124.3, 123.6, 123.4, 103.9, 103.4, 103.2, 103.1, 60.2, 56.0, 55.9, 55.2, 54.0, 33.8, 31.3, 
21.6 (4 peaks are missing due to incidental equivalence). Spectroscopic properties were 
consistent with those reported in the literature.28 The enantiopurity was determined to be 
88% ee by chiral HPLC analysis (chiralcel AD-H, 0.46 cm x 25 cm, 25% iPrOH/hexanes 
0.1% Et3N, 1.0 mL/min, λ = 254 nm, RT = 10.0 and 12.7 min). 
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Deuterium Labeling Studies 
 
(1R,2S)-(–)-tert-Butyl [2d-(2-benzylpyrrolidine)]-1-carboxylate (II-31t). The general 
procedure was employed for the coupling of bromobenzene (126 mg, 0.8 mmol) with 
(E)-tert-butyl-5-d- pent-4-en-1-ylcarbamate II-24d (75 mg, 0.4 mmol, 80% d-
incorporation). This procedure afforded 66 mg (63%) of the title compound as a pale 
yellow oil with 80% d-incorporation. No loss or migration of the isotope was observed. 
[α]23D –1.0 (c 1.0, CH2Cl2). 1H NMR (400 MHz, C6D5CD3, 100 ºC) δ 7.13–6.98 (m, 5 H), 
4.00–3.94 (m, 1 H), 3.32–3.23 (m, 1 H), 3.17–3.04 (m, 2 H), 1.50–1.30 (m, 13 H); 13C 
NMR (125 MHz, C6D5CD3, 100 °C) δ 154.2, 139.8, 129.7, 128.5, 126.3, 78.6, 58.9, 46.8, 
40.4 (m), 29.9, 28.7, 23.3; IR (film) 1686, 1394 cm-1; MS (ESI) 285.1685 (285.1689 
calcd for C16H22DNO2, M + Na+). The enantiopurity was determined to be 86% ee by 
chiral HPLC analysis (R,R-Whelk-O 1, 25 cm x 4.6 mm, 1% iPrOH/hexanes, 1 mL/min, 
λ = 254 nm, RT = 10.4 and 11.2 min). The relative stereochemistry of II-31t was 




43). A flame dried flask was cooled under a stream of nitrogen and charged with (1R,2S)-
(-)-tert-butyl [2d-(2-benzylpyrrolidine)]-1-carboxylate II-31t (60 mg, 0.23 mmol) and 4-
dimethylaminopyridine (85 mg, 0.69 mmol). The flask was purged with nitrogen, CH2Cl2 
(6 mL) was added, and the resulting solution was cooled to 0 ºC. A solution of triflic 
anhydride (0.2 mL, 1.15 mmol) in CH2Cl2 (2 mL) was added dropwise, and the resulting 
cloudy mixture was allowed to warm to rt and stir overnight. A solution of Na2CO3 (10 
mL, 1 M) was added, the resulting mixture was transferred to a separatory funnel, and the 
layers were separated. The aqueous layer was extracted with CH2Cl2 (2 x 5 mL) and the 
combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in 
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vacuo. The crude product was purified by flash chromatography on silica gel to afford 22 
mg (51%) of the title compound as a colorless solid with ~80% deuterium incorporation 
as judged by 1H NMR analysis. The relative stereochemistry was assigned by comparison 
of 1H NMR data to those previously obtained for this known compound.9f [α]23D –140.0 
(c 1.0, CH2Cl2); 1H NMR (500 MHz, C6D6) δ 8.51–8.47 (m, 1 H), 7.11–7.06 (m, 2 H), 
6.81–6.77 (m, 1 H), 3.62–3.56 (m, 1 H), 3.46–3.38 (m, 1 H), 3.12–3.05 (m, 1 H), 2.15 (d, 
J = 13.5 Hz, 1 H), 1.47–1.41 (m, 1 H), 1.37–1.30 (m, 1 H), 1.17–1.07 (m, 1 H), 0.98–0.90 
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Chapter 3 
Preliminary Studies on Enantioselective Pd-Catalyzed Desymmetrization Reactions 
for the Synthesis of cis-2,5-Disubstituted Pyrrolidines 
3.1 Introduction 
The enantioselective desymmetrization of prochiral or achiral compounds is one of 
the most common and powerful methods for the synthesis of enantioenriched molecules.1 
Desymmetrization of symmetrical substrates can be achieved with a chiral, nonracemic 
reagent or catalyst, where the differentiation of rate between two enantiotopic groups 
allow, in principle, for selective formation of one enantioenriched product. In addition, 
desymmetrization reactions can provide enantioenriched products that contain quaternary 
centers that are challenging to synthesize. Desymmetrization reactions have also been 
used in a variety of transformations for the synthesis of enantioenriched alcohols, amines, 
bicyclic heterocycles and natural products.2 This chapter will focus on our ongoing 
efforts toward the development of an enantioselective Pd-catalyzed desymmetrization 
carboamination reaction. Preliminary studies with readily available chiral ligands have 
identified promising ligand scaffolds.  
3.2 Enantioselective Pd-Catalyzed Desymmetrization Reactions 
In order to provide context for our work in this area, a brief summary of Pd-
catalyzed desymmetrization reactions that involve alkene insertion is presented in this 
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section. The Heck reaction is an important method for carboncarbon bond formation, 
and the first examples of asymmetric Heck reactions were independently reported by 
Shibasaki and Overman in 1989.3 Shibasaki’s report described the first enantioselective 
desymmetrization reaction of racemic alkenyl iodide III-1, which afforded cis-decalin 
derivative III-2. A catalyst composed of Pd(OAc)2, and (R)-BINAP was able to effect the 
formation of III-2 in 74% yield and 46% ee (Scheme 3-1). Further studies led to the use 
of alkenyl triflate substrates III-3 and III-4, which respectively led to III-5 and III-6 
with drastic improvements in enantioselectivity (up 91% ee).4 It is hypothesized that 
Heck reactions employing aryl and alkenyl triflates coupling partners proceed via a 
cationic pathway, where stable bidentate phosphine palladium interactions are potentially 
responsible for high enantioselectivities.3c One of the benefits of employing triflate 
coupling partners is that costly silver salts can be replaced with inexpensive bases such as 
K2CO3, and hydrocarbon solvents could be used in place of NMP.  
Scheme 3-1. First Enantioselective Heck Desymmetrization Reaction 
 
 More recently, phosphoramidites and amino acid derivatives have been identified 
as efficient ligands for asymmetric Heck desymmetrization reactions.5,6 As shown in 
Scheme 3-2, Feringa and coworkers developed an intramolecular asymmetric Heck 
reaction of cyclohexadienones III-7 to generate tricyclic III-8, which is catalyzed by 
Pd(OAc)2 and phosphoramidite ligand III-L1 (Scheme 3-2).5 It is important to note that 
the stereocenter generated is not created at the site of CC bond formation, but rather 
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through a desymmetrization of the substrate itself. The use of an aryl triflate derivative of 
III-7 resulted in lower reaction conversions, and the addition of silver salts did not lead to 
improvement.  
Scheme 3-2. Pd/Phosphoramidite Catalyzed Desymmetrization Reaction 
 
Yu and coworkers have described a unique enantioselective CH olefination 
reaction catalyzed by α-amino acids.6 The reaction couples diphenylacetic acid 
derivatives III-9 with styrene derivatives using Pd(OAc)2 and Boc-Ile-OH•H2O (III-L2) 
as a catalyst, to provide products such as III-10 in good yields and high selectivity. The 
authors propose that upon CH activation, the reaction proceeds through a boat-like 
intermediate (III-11), which the authors propose is responsible for high asymmetric 
induction for the formation of III-10 (Scheme 3-3).  
Scheme 3-3. Enantioselective Pd-Catalyzed CH Olefination  
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 Pd-catalyzed asymmetric allylic substitution reactions have also emerged as an 
efficient method for the construction of carboncarbon and carbonheteratom bonds. A 
wide range of nucleophiles can be employed and a variety of functional groups can be 
tolerated.2a Trost reported an enantioselective desymmetrization reaction of Boc-activated 
cyclopenten-1,4-diol III-12 for the synthesis of III-15 via successive Pd-catalyzed 
asymmetric amination reactions in one pot (Scheme 3-4).7 Treatment of III-12 and N-
methoxyamide III-13 with catalytic Pd2(dba)3, III-L3 and HOAc in CH2Cl2 facilitated 
desymmetrization of III-12 to form intermediate III-14. After 3.5 h, another portion of 
the Pd2(dba)3 and III-L3 was added to catalyze a subsequent intramolecular allylic 
amination reaction. Piperazone III-15 was prepared in 82% yield and 97.5% ee, and 
subsequently served as an intermediate in the synthesis of ()-agelastatin A. 
Scheme 3-4. Asymmetric Pd-Catalyzed Allylic Amination Reactions 
 
As discussed in Chapter 2, we have recently developed Pd-catalyzed asymmetric 
carboamination reactions for the synthesis of 2-(arylmethyl)- and 2-
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(alkenymethyl)pyrrolidines.8 However, asymmetric carboamination reactions of 
substituted N-Boc-pent-4-enylamines were unsuccessful. We wanted to explore and 
develop an enantioselective Pd-catalyzed carboamination reaction for the 
desymmetrization of III-16 for the synthesis of enantiomerically enriched cis-2,5-
disubstituted pyrrolidines III-17, which generates 2 stereocenters and provides 
opportunities for further functionalization (Scheme 3-5).  
Scheme 3-5. Synthetic Strategy for cis-2,5-Disubstituted Pyrrolidines 
 
3.3 Previous Studies and Substrate Synthesis 
Initial studies were conducted by Dr. Qifei Yang, a former post-doctoral researcher 
in the group, for the coupling of III-16a and 2-bromonaphthalene with Pd2(dba)3 and 
chiral ligands. As shown below in Scheme 3-6, monodentate phosphine ligand (S)-
NMDPP provided III-17a in 80% yield and 48% ee. Bis-phosphine ligands and 
monodentate phosphoramidite ligands such as (R)-BINAP and (R)-MONOPHOS 
provided low yields and enantioselectivities of pyrrolidine product III-17a.  
Scheme 3-6. Preliminary Studies 
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From our prior studies on asymmetric carboamination reaction of γ-aminoalkenes, 
the N-protecting group (Boc) on the substrate and the use of phosphoramidite ligands 
were important for high enantioselectivity. Thus, we prepared N-Boc aminodialkene III-
16b from alcohol III-19, which was generated by Grignard addition of homoallyl 
magnesium bromide to ethyl formate (III-18). Nucleophilic displacement of the alcohol 
on III-19, followed by hydrazine monohydrate cleavage to the amine and Boc protection 
provided III-16b (Scheme 3-7).  
Scheme 3-7. Substrate Synthesis 
 
3.4 Ligand Screen 
In our initial experiments, we examined the coupling of N-Boc aminodialkene III-
16b and 2-bromonaphthalene using commercially available bis-phosphines, monodentate 
phosphines and phosphite ligands (Table 3-1). The coupling of III-16b and 2-
bromonaphthalene provided III-17b in good diastereoselectivity for the cis-2,5-
disubstituted pyrrolidines (20:1 dr), however, low yields and enantioselectivities were 
observed. The preference for the cis-2,5-disubstituted pyrrolidine can be explained 
through minimization of A(1,3)-strain in the transition state leading to the favored 
product.9 Bis-phosphine ligands such as (S)-BINAP (III-L4) were ineffective for 
enantioenrichment. Reexamination of monodentate ligand (S)-NMDPP (III-L12) resulted 
in base-mediated decomposition of III-16b, which is in sharp contrast to the good yield 
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and promising enantioselectivities obtained for N-Ph aminodialkene derivative III-16a 
(Table 3-1). It seems that smaller monodentate ligands are more effective for 
desymmetrization reactions of N-aryl aminodialkene derivatives than N-Boc 
aminodialkenes. The poor reactivity and selectivity observed with III-16b is consistent 
with our prior results on reactions employing N-Boc-pent-4-enylamines substrates, in 
which bidentate bis-phosphines, monodentate phosphines, and phosphites were 
ineffective for enantioselective carboamination reactions.8 
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Table 3-1. Initial Ligand Screena,b,c 
a Conditions: Reactions were conducted on a 0.15 mmol scale with 1.0 equiv substrate, 1.2 equiv 2-
bromonaphthalene, 1.2 equiv NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand, toluene (0.15 M), 90-110 °C, 12-15
h. b Enantiomeric excess was determined by chiral HPLC analysis. c Negative ee values indicate the major
enantiomer was the opposite configuration of other examples in the table.
1 mol % Pd2(dba)3
4 mol % Ligand


























































































Our recent success with phosphoramidite ligands for the enantioselective synthesis 
of 2-substituted pyrrolidines prompted us to explore these ligands for enantioselective 
desymmetrization reactions. As shown in Table 3-2, promising results were obtained with 
BINOL-derived ligands (S,S,S)-III-L19 and (S,R,R)-III-L20 for the coupling of III-16b 
and 2-bromonaphthalene. In contrast to previous studies on asymmetric carboamination 
reactions, better results in the desymmetrization reactions are obtained with a BINOL 
backbone, rather than a spirobiindane backbone. (R)-Siphos-PE (III-L24) provided 
comparable enantioselectivities (53% ee) to ligand (S,R,R)-III-L19, but III-17b was 
produced in lower yield (11% yield). 
In general, side products were not observed in these reactions, and it is likely that 
the modest yields result from base-mediated substrate decomposition (Boc decomposition 
and alkene isomerization). Weak bases such as K2CO3 and Cs2CO3 led to low 
conversions. Increased yields could be obtained by employing higher catalyst loading 
similar to previously reported asymmetric carboamination reactions.8  
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Table 3-2. Phosphoramidite Ligand Screena,b,c 
a Conditions: Reactions were conducted on a 0.15 mmol scale with 1.0 equiv substrate, 1.2 equiv 2-
bromonaphthalene, 1.2 equiv NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand, toluene (0.15 M), 90 °C, 12-15 h. b
Enantiomeric excess was determined by chiral HPLC analysis. c Negative ee values indicate the major
enantiomer was the opposite configuration of other examples in the table.
1 mol % Pd2(dba)3
4 mol % Ligand
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18% yield, 13% ee
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3.5 Summary and Future Directions 
Our preliminary studies on enantioselective Pd-catalyzed desymmetrization 
reactions have yielded promising results with chiral BINOL-derived phosphoramidite 
ligands, which provide enantioselectivities up to 71% ee. In these desymmetrization 
reactions, the BINOL backbone is important for reactivity and selectivity, which is in 
contrast to previously reported asymmetric carboamination reactions that employ 
spirobiindane-derived phosphoramidite (R)-Siphos-PE for the synthesis of 
enantioenriched 2-substituted pyrrolidines. Future directions include synthesis of other 
BINOL-derived phosphoramidite ligand analogs (Figure 3-1), establishing the absolute 
stereochemistry of cis-2,5-disubstituted pyrrolidine products and examining other N-aryl 
aminodialkene substrates with monodentate ligands similar to (S)-NMDPP.  




























All reactions were carried out in flame-dried glassware under an atmosphere of 
nitrogen. Tris(dibenzylideneacetone)dipalladium (0) were purchased from Strem 
Chemical Co. and used without further purification. All ligands were either purchased 
from commercial sources (Strem Chemical Co. or Aldrich Chemical Co.) or used without 
further purification, or were synthesized according to published procedures.10 2-
bromonapthalene was obtained via commercial sources and nona-1,8-dien-5-ol (III-19) 
was synthesized according to literature procedure.11 All solvents were purified with a 
GlassContour solvent purification system. The yields reported in the supporting 
information describe the result of a single experiment.  
 
Experimental Procedures and Compound Characterization Data: 
 
Synthesis of Substrate III-16b 
NO O
 
2-(Nona-1,8-dien-5-yl)isoindoline-1,3-dione (S1). A flame dried flask round bottom 
flask was charged with nona-1,8-dien-5-ol (2.38 g, 17 mmol), PPh3 (4.9 g, 18.7 mmol), 
phthalimide (2.75 g, 18.7 mmol), THF (85 mL) and cooled to 0 °C. DIAD (4.0 mL, 20.4 
mmol) was added dropwise over the course of 30 minutes and slowly warmed up to rt 
and stirred overnight. The mixture was concentrated and diluted with a 2:1 mixture of 
hexanes/ether (50 mL). The solution was filtered through a pad of celite and concentrated 
in vacuo. The crude product was purified by column chromatography on silica gel to 
afford 3.61 g (79%) of 2-(nona-1,8-dien-5-yl)isoindoline-1,3-dione as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.80 (dd, J = 3.0, 5.5 Hz, 2 H), 7.69 (dd, J = 3.0, 5.5 Hz, 2 
H); 5.785.69 (m, 2 H), 4.95 (q, J  = 1.5 Hz, 1 H), 4.92 (q, J = 1.5 Hz, 1 H), 4.87 (dd, J 
= 1.5 Hz, 10.0 Hz, 2 H), 4.23 (quint, J  = 5.0 Hz, 1 H), 2.502.16 (m, 2 H), 2.061.94 
(m, 4 H), 1.821.74 (m, 2 H); 13C NMR (125 MHz, CDCl3) 168.6, 137.4, 133.8, 131.8, 
123.0, 115.1, 51.1, 31.5, 30.8; IR (film) 1707, 1372 cm-1; MS (ESI) 270.1488 (270.1489 






tert-Butyl nona-1,8-dien-5-ylcarbamate (III-16b). A flame dried round bottom flask 
was charged with 2-(nona-1,8-dien-5-yl)isoindoline-1,3-dione S1 (3.61 g, 13.4 mmol) 
and 95% EtOH (70 mL). Hydrazine monohydrate (65%, 2 mL, 26.8 mmol) was added 
and the mixture was heated at 80 °C until starting material had been consumed as judged 
by TLC (ca. 6 h). Boc2O (6.1 g, 28.1 mmol) was added portion wise and the solution was 
stirred overnight. The mixture was concentrated and diluted with water (50 mL). The 
solution was extracted with CH2Cl2 (3 x 50 mL) and the combined organic layers were 
dried over Na2SO4, filtered and concentrated in vacuo. The crude mixture was purified by 
column chromatography on silica gel to afford 1.55 g (48%) of the title compound as a 
white solid. mp 38-40 °C; 1H NMR (500 MHz, CDCl3) δ 5.865.76 (m, 2 H), 5.204.92 
(m, 4 H), 4.304.24 (m, 1 H), 3.643.56 (m, 1 H), 2.162.02 (m, 5 H), 1.661.50 (m, 2 
H), 1.43 (s, 9 H); 13C NMR (125 MHz, CDCl3) 155.6, 138.2, 114.8, 78.9, 49.9, 34.8, 
30.2, 28.4; IR (film) 3389, 1705, 1364 cm-1; MS (ESI) 240.1957 (240.1958 calcd for 
C14H25NO2, M + H+). 
 
General Procedure for the Enantioselective Pd-Catalyzed Desymmetrization: 
 
(±)-(2R*,5R*)-tert-butyl 2-(but-3-en-1-yl)-5-(naphthalen-2-ylmethyl)pyrrolidine-1-
carboxylate (III-17b). A flame-dried Schlenk tube was cooled under a stream of 
nitrogen and charged with charged with Pd2(dba)3 (1.4 mg, 1 mol % complex, 2 mol % 
Pd), chiral ligand (4 mol %) and NaOtBu (17 mg, 0.18 mmol). The tube was purged with 
nitrogen, then a solution of the amine substrate III-16b (36 mg, 0.15 mmol) and 2-
bromonaphthalene (37 mg, 0.18 mmol) in toluene (1 mL, 0.15 M) was added via syringe. 
The mixture was heated to 90 °C or 110 °C with stirring until the starting material had 
been consumed as judged by GC or 1H NMR analysis (ca. 12-15 h). The reaction mixture 
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was cooled to room temperature, quenched with saturated aqueous NH4Cl (2 ml) and 
diluted with EtOAc (5 ml). The layers were separated and the aqueous layer was 
extracted with EtOAc (2 x 5 ml). The combined organic layers were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
flash chromatography on silica gel to afford the title compound as a pale yellow oil as a 
1:1 mixture of rotomers. The data are for the mixture. 1H NMR (500 MHz, CDCl3) δ 
7.867.75 (m, 3 H), 7.64 (s, 1 H), 7.487.32 (m, 3 H), 5.865.74 (m, 1 H), 5.064.92 
(m, 2 H), 4.314.02 (m, 2 H), 3.903.56 (m, 1 H), 2.802.66 (m, 1 H), 2.181.84 (m, 4 
H), 1.781.70 (m, 2 H), 1.681.62 (m, 1 H), 1.581.40 (m, 9 H), 1.361.24 (m, 1 H); 
13C NMR (125 MHz, CDCl3)  δ 154.9, 138.3, 138.1, 136.6, 133.5, 132.1, 127.7, 127.5, 
127.4, 125.8, 125.2, 114.7, 114.4, 79.1, 78.8, 59.9, 58.3, 49.9, 42.1, 40.9, 34.8, 34.7, 30.7, 
30.1, 29.2, 28.7, 28.6, 28.5, 28.4; IR (film) 1708, 1393, 1366, 905, 727 cm-1; MS (ESI) 
366.2424 (366.2428 calcd for C24H31NO2, M + H+). The enantiomeric excess for 
compounds III-17b in Table 3-1 and Table 3-2 were determined by chiral HPLC analysis 
(chiralcel AD-H, 0.46 cm x 25 cm, 1% iPrOH/hexanes, 1.0 mL/min, λ = 254 nm, RT = 
5.3(minor) and 6.4(major) min). The absolute configuration of the pyrrolidine products have 
yet to be determined.  
The diastereoselectivity was determined by TFA-mediated deprotection of crude 
product of III-17b to provide III-20 as shown below, and was found to be 20:1 dr as 
judged by 1H NMR analysis. The stereochemistry of the major diastereomer of 
compound III-17b was determined by 1H NMR nOe analysis of the corresponding 
derivative III-20.  
 
 
(±)-(2R,5R)-2-(but-3-en-1-yl)-5-(naphthalen-2-ylmethyl)pyrrolidine (III-20). A 
flame-dried flask was charged with III-17b (55 mg, 0.15 mmol) and CH2Cl2 (1 mL). The 
solution was cooled to 0 °C, trifluoroacetic acid (0.1 mL, 1.5 mmol) was then added 
slowly and the resulting mixture was stirred at rt for 1 h. The crude mixture was 
concentrated in vacuo. The crude product was redissolved in CH2Cl2 (5 mL), and 2 M 
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NaOH (5 mL) was added. The layers were separated and the aqueous layer was extracted 
with CH2Cl2 (2 x 5 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo to afford 38 mg (95%) of the title compound as a yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.827.77 (m, 3 H), 7.67 (s, 1 H), 7.44 (dquint, J = 1.5, 
7.0 Hz, 2 H), 7.37 (dd, J = 1.5, 8.5 Hz, 1 H), 5.00 (dd, J = 1.5, 17.0 Hz, 1 H), 4.94 (d, J = 
10.5 Hz, 1 H), 3.34 (quint, J  = 7.0 Hz, 1 H), 3.012.94 (m, 2 H), 2.932.87 (m, 1 H), 
2.142.00 (m, 2 H), 1.901.74 (m, 3 H), 1.651.46 (m, 3 H), 1.411.33 (m, 1 H), 1.27 
(s, 1 H); 13C NMR (125 MHz, CDCl3) δ 138.6, 137.7, 133.5, 132.0, 127.8, 127.6, 127.5, 
127.4, 127.1, 125.8, 125.2, 114.3, 60.4, 58.5, 42.9, 35.9, 31.6, 30.8, 30.7;  IR (film) 3337 
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Chapter 4 
Enantioconvergent Synthesis of (+)-Aphanorphine via Asymmetric  
Pd-Catalyzed Carboamination 
4.1 Introduction  
The tricyclic alkaloid aphanorphine (IV-1) is a benzomorphan derived natural 
product isolated from the blue-green algae Aphanizomenon flos-aquae in 1988 by 
Shimizu and Clardy.1 Although to date no biological activity of aphanorphine has been 
reported, aphanorphine shares common structural features with other bioactive 
(analgesic) benzomorphan alkaloids, such as eptazocine (IV-2), pentazocine (IV-3), and 
morphine (IV-4) (Figure 4-1).  
Figure 4-1. 3-Benzomorphan Alkaloids 
 
4.2 Previous Enantioselective Syntheses of Aphanorphine 
Aphanorphine has been the target of numerous synthetic efforts over the past 
twenty-three years.2-4 Previous enantioselective syntheses of aphanorphine have involved 
two main strategies: 1) CN bond formation of Ring C via intermediate IV-5 which 
contains the benzylic quaternary carbon center (Figure 4-2, path a),2 or 2) CC bond 
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formation of Ring B and the benzylic quaternary carbon center through Friedel-Crafts 
alkylation of IV-6 or radical cyclization of IV-7 respectively (Figure 4-2, path b).3, 4  
Figure 4-2.2-4 Strategies for the Enantioselective Synthesis of Aphanorphine 
 
 
4.21 Enantioselective Synthesis of ()-Aphanorphine via C-N Bond Formation (path 
a)  
Aziridination/Reductive Cleavage Strategy 
 Two years after the isolation of aphanorphine by Shimizu and Clardy, Takano 
reported the first enantioselective total synthesis of ()-aphanorphine.2a As shown below 
in Scheme 4-1, Takano’s strategy for CN bond formation was aziridination and 
reductive cleavage of IV-5 to form ()-aphanorphine. Amine IV-5 could be accessed via 
reduction of ester IV-8 followed by SN2 displacement with an amine nucleophile. The 
ester IV-8 could come from intermediate IV-9 via a Pummerer reaction followed by 
Friedel-Crafts ring closure. Conjugate addition and Wharton rearrangement of readily 
available enone IV-11 could provide isomeric enone IV-10, which upon hydrogenation 

































As shown in Scheme 4-2, readily available (+)-dienone IV-11 was converted to 
IV-12 via 1,4-conjugate addition of 3-methoxyphenylmagneisum bromide in the presence 
of copper(I) bromide followed by retro-Diels Alder to afford enone IV-12 in 87% yield. 
Wharton rearrangement facilitated by H2O2 and hydrazine monohydrochloride converted 
IV-12 into an allylic alcohol, which was then oxidized to provide isomeric enone IV-13 
in 62% yield. Enone IV-13 was then hydrogenated and subsequent alkylation with 
trimethylene dithiotosylate and KOtBu furnished IV-14 in 53% yield. Upon 
saponification with KOH and immediate exposure to diazomethane, cyclic ketone IV-14 
was converted to ring-opened ester IV-15 in 79% yield. Treatment of IV-15 with m-
CPBA generated monosulphoxide IV-16 as a mixture of diastereomers, which were 
converted to a single regioisomer IV-19 upon exposure to TFAA in refluxing toluene. It 
is believed that TFAA-catalyzed Pummerer reaction occurs via transient intermediates 
IV-17 and IV-18, which facilitates cyclization and loss of 1,2-dithiolane and 
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trifluoacetate ion. Intermediate IV-19 has also been targeted by many other groups for the 
formal synthesis of ()-aphanorphine.2b-2f 
Scheme 4-2. Synthesis of Key Intermediate IV-19 
 
 Ester IV-19 was reduced to the corresponding alcohol, which was converted to 
amine IV-20. A Nagata reaction with Pb(OAc)4 and K2CO3 effected efficient 
intramolecular aziridination across the alkene of IV-20 to yield an unstable aziridine, 
which was immediately exposed to methyl fluorosulphonate to provide stable quaternary 
ammonium salt IV-21. Meyers’ has also reported a synthesis of ()-aphanorphine via 
amino mercuration of common N-methylated intermediate IV-20.2c The ammonium salt 
IV-21 was converted to IV-22 via reduction with lithium aluminium hydride, which 
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selectively cleaved the benzylic bond. Amine IV-22 was obtained in 24% yield over 3 
steps from IV-20.  Finally, BBr3-mediated deprotection of IV-22 provided ()-
aphanorphine in 65% yield (Scheme 4-3).   
Scheme 4-3.2a Completion of the Synthesis of ()-Aphanorphine 
 
The first enantioselective synthesis of ()-aphanorphine was accomplished in 18 
steps and 1.3% overall yield.2a Takano’s synthesis utilizes an interesting Pummerer 
reaction of monosulphoxide IV-16 and a Nagata aziridination for CN bond formation 
of ring C.  
4.22 Enantioselective Synthesis of ()-Aphanorphine via C-C Bond Formation (path 
b) 
Friedel-Crafts Alkylation Cyclization Strategy  
An efficient and facile formal synthesis of ()-aphanorphine was reported by Zhai 
and coworkers.3a In Zhai’s strategy, ring B of the tricycle could be constructed via 
Friedel-Crafts alkylation of pyrrolidinol IV-23 with stereospecific formation of the 
benzylic carbon stereocentercenter. Rings A and C could be generated from 4-
methoxyphenylacetaldehyde IV-26, where a Roush methallylation of IV-26 generates 
 89
chiral homoallylic alcohol IV-25, which could be converted to epoxy amine IV-24 and 
then to tertiary alcohol IV-23 (Scheme 4-4).3a   

























4-methoxyphenylacetaldehyde IV-26 was obtained via oxidation of commercially 
available 4-methoxyphenethyl alcohol.5 As shown in Scheme 4-5, the Roush 
methallylation of 4-methoxyphenylacetaldehyde IV-26 with methallylmagneisum 
chloride and (+)-DIP-chloride provided (R)-homoallylic alcohol IV-25 in 85% yield and 
95% ee. Stereoselective epoxidation of IV-25 with 2 mol % VO(acac)2 and tert-butyl 
hydrogen peroxide yielded epoxide IV-27a-b in 96% yield as a 2:1 mixture of 
inseparable diastereomers. Treatment of IV-27a-b with HN3, PPh3 and DEAD in benzene 
provided azides IV-28a-b in good yield. Other nucleophiles such as (Boc)NHTs and 
(Cbz)NHTs resulted in low yields or elimination products. Selective hydrogenation of 
azides IV-28a-b was achieved with Lindlar’s catalyst and exposure to TsCl and 
triethylamine in ether at room temperature produced sulfonamides IV-29a (65%) and IV-
29b (33%) in 98% overall yield. At this point, the diastereomers were separated by 
column chromatography. An intramolecular epoxy displacement with refluxing NaH in 
benzene converted IV-29a to pyrrolidinol IV-30 in 88% yield. It is important to note that 
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under the same reaction conditions, diastereomer IV-29b did not undergo cyclization. 
Lewis-acid catalyzed intramolecular Friedel-Crafts cyclization of IV-30 with AlCl3 
formed the benzylic quarternary carbon center and provided tricyclic product IV-31 in 
88% yield and 99% ee. Finally, reductive desulfurization with Red-Al in refluxing xylene 
provides IV-32 in 96% yield and N-methylation of the amine with formaldehyde and 
NaBH3CN in MeOH at room temperature affords IV-33 in 98% yield.  
Scheme 4-5.3a Enantioselective Synthesis of ()-Aphanorphine 
 
 The formal synthesis of ()-aphanorphine was accomplished in 10 steps and in 
22% overall yield (including a presumed yield of 61-88% for the final step).2a,2f,2g,3 The 
key features of this reaction are a base-promoted intramolecular endo epoxy displacement 
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for the formation of pyrrolidinol IV-30 and Lewis-acid promoted Friedel-Crafts 
cyclization to generate the benzylic quaternary carbon center and construct the tricyclic 
core of ()-aphanorphine. Although the vanadium-catalyzed epoxidation produced a 
mixture of inseparable diastereomers, the diastereomers were functionalized and later 
separated. Several other syntheses of aphanorphine have employed similar Friedel-Crafts 
alkylation strategies for the formation of the quaternary carbon stereocenter.3  
Aryl Radical Cyclization Strategy 
 A Bu3SnH-mediated aryl radical cyclization was employed by Ishibashi for the 
construction of the benzylic quaternary center of ()-aphanorphine (IV-1).4a The key 
transformation of Ishibashi’s strategy was a 6-exo aryl radical cyclization of highly 
functionalized pyrrolidine IV-36 to generate the tricyclic core IV-34 via radical 
intermediate IV-35.  IV-36 can be prepared in four steps from pyrrolidine IV-37, which 
can be generated from trans-4-hydroxy-L-proline (IV-38) (Scheme 4-6).  
Scheme 4-6. Ishibashi’s Retrosynthetic Analysis 
 
 Ishibashi’s total synthesis of ()-aphanorphine is described below in Scheme 4-
7.4a Pyrrolidine IV-39 was prepared from trans-4-hydroxy-L-proline (IV-38) via 
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esterification and protection of the amino and hydroxyl groups according to a procedure 
developed by Joullié and coworkers.6 Treatment of IV-39 with LiHMDS generated the 
lithium enolate and alkylation with 2-bromo-4-methoxybenzyl bromide provided a 4:1 
mixture of IV-40 and its’ inseparable diastereomer. Desilylation of IV-40 with TBAF 
and recrystallization from n-hexaneEt2O produced alcohol IV-41 as one diastereomer 
in 68% yield. Oxidation of alcohol IV-41 and a Horner-Wittig reaction with the lithium 
salt of PhSCH2P(O)Ph2 in the presence of CeCl3 followed by treatment with NaH 
provided radical precursor IV-42 in 78% yield. Treatment of IV-42 with Bu3SnH and 
AIBN facilitated 6-exo radical cyclization to provide tricyclic IV-43 in 76% yield. In the 
absence of the sulfur substituent on IV-42, radical cyclization proceeded in low yields, 
clearing demonstrating the importance of the phenylthio group for radical-stabilization 
and cyclization. Refluxing IV-43 in 5 N NaOH provided carboxylic acid IV-44, which 
was condensed with 2-mercaptopyridine. Barton decarboxylation of the thiohydroxamate 
ester with Bu3SnH and AIBN produced IV-45 in 52% yield. Desulfurization, 
deprotection of the benzyloxycarbonyl group and reductive methylation of IV-46 was 
accomplished in one pot with Raney Ni in MeOH. The synthesis of ()-aphanorphine 
was finished via BBr3-mediated demethylation of IV-46. However, no yield was reported 
for this last step.   
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87% yield over 3 steps
 
 Ishibashi’s synthesis of ()-aphanorphine was completed in 13 steps starting from 
commercially available trans-4-hydroxy-L-proline IV-38 (IV-46 was obtained in 11% 
overall yield). This synthesis utilized a Bu3SnH-mediated aryl radical cyclization for the 
construction of the tricycle of IV-1 with concomitant formation of the benzylic 
quaternary center, which represents a unique and efficient method for the synthesis of 3-
benzomorphane alkaloids.  
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4.23 Summary  
Methods for the enantioselective synthesis of ()-aphanorphine have either used 
CN bond formation (Figure 4-2, path a) or CC bond formation (Figure 4-2, path b) 
for the synthesis of the tricyclic core of ()-aphanorphine. Many of these syntheses of 
aphanorphine have employed chiral-pool starting materials or use stoichiometric amounts 
of a chiral reagent or auxiliary to set the absolute stereochemistry of the natural product. 
In contrast, asymmetric catalysis has occasionally been used to control the absolute 
configuration in aphanoprhine synthesis.2d,2l,4d,4f In these instances, the stereocenter was 
generated via reduction or desymmetrization of a prochiral starting material. One strategy 
that would enable facile access to aphanorphine and other 3-benzomorphan alkaloids 
would be a catalytic enantioconvergent synthesis, in which both enantiomers of a 
racemic starting material are converted to a single enantiomerically enriched product.  
4.3 Enantioconvergent Strategies in the Literature 
Enantioconvergent transformations or strategies have potential for significant 
potential synthetic utility, as they effect the conversion of both enantiomers of a racemic 
starting material to a single enantiomerically enriched product.7,8 Enantioconvergent 
strategies have been employed in the construction of natural products,7c,7d,9 where kinetic 
resolution methods are used to facilitate separation of two enantiomers. The enantiomer 
with the “correct” configuration is directly carried on towards the desired target, whereas 
the stereochemical configuration of the other enantiomer is inverted through one or more 
transformations. In most instances the stereochemical correction is achieved through 
functional-group interconversions, such as Mitsunobu reactions, oxidation/reduction 
sequences, and similar processes.7c,7d,9  
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In 2005, Stoltz and coworkers described the first example of a catalytic 
enantioconvergent method for the synthesis of quaternary stereocenters starting from 
racemates that contain quaternary stereocenters. The method utilizes a catalytic 
asymmetric decarboxylative allylation to convert racemic α-substituted 2-
carboxyallylcyclohexanones into highly enantioenriched cycloalkanones (Scheme 4-8).7b  
For example, treatment of (±)-IV-47 with a catalyst derived from Pd2(dba)3 and (S)-t-
BuPhox in Et2O produced allyl ketone (S)-IV-49 in 97% yield and 92% ee. The 
mechanism presumably proceeds through loss of CO2 to form achiral Pd-enolate IV-48, 
which subsequently undergoes enantioselective allylation to produce (S)-IV-49 in high 
enantiopurity. This enantioconvergent methodology has also been applied toward the 
enantioselective total synthesis of (+)-Cassiol and (+)-Hamigeran B.7c,7d  
Scheme 4-8. Pd-Catalyzed Decarboxylative Allylation of Racemic β-Ketoesters 
 
There is one total synthesis of ()-aphanorphine that employed an 
enantioconvergent strategy, where at the outset of the synthesis, racemic ene-diol IV-50 
was resolved to enantiopure intermediates (+)-IV-51 and ()-IV-52 via lipase-catalyzed 
transesterification.2g Both products were converted to the corresponding enantiomeric 
enones (+)-IV-53 and ()-IV-54 through deprotection and oxidation sequences (Scheme 
4-9).  
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As shown below in Scheme 4-10, enones (+)-IV-53 and ()-IV-54 were treated 
with 3-methoxyphenylmagnesium bromide in the presence of catalytic CuBr•SMe2, and 
subsequent retro-Diels Alder in refluxing diphenyl ether provided (+)-IV-55 and ()-IV-
56 in good yields. To make this synthesis enantioconvergent, enone ()-IV-56 was 
converted to (+)-IV-55 via Wharton rearrangement in 53% yield over 3 steps without loss 
of enantiomeric purity. Optically active enone (+)-IV-55 was then used to synthesize 
()-aphanorphine in 12 steps. This enantioconvergent synthesis of ()-aphanorphine 
afforded the natural product in 23 steps (longest linear sequence reported) from 
commercially available materials.   
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1) 10 mol % CuBr•SMe2
3-methoxyphenyl MgBr
TMSCl, HMPA, -70 °C to rt











1) 10 mol % CuBr•SMe2
3-methoxyphenyl MgBr
TMSCl, HMPA, -70 °C to rt











In the rest of this chapter, we report an alternative, catalytic enantioconvergent 
approach to the construction of aphanorphine, in which a racemic intermediate is 
transformed into two enantiomerically enriched diastereomers through asymmetric 
catalysis. The two diastereomers are then directly transformed to one enantioenriched 
product in an enantioconvergent C–C bond-forming step that generates an all-carbon 
quaternary stereocenter. Our approach enables us to access either enantiomer of 
aphanorphine from one common intermediate.  
4.4  Catalytic Enantioconvergent Strategy for the Synthesis of (+)-Aphanorphine 
As an alternative to existing strategies for the asymmetric synthesis of 
aphanorphine, we sought to develop an enantioconvergent route whereby a simple 
racemic starting material could be transformed to the enantiomerically enriched alkaloid 
(Scheme 4-11).10 It seemed that two key transformations could be used to accomplish this 
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goal: an enantioselective Pd-catalyzed carboamination reaction that was recently 
developed in our laboratory,11 and an intramolecular Friedel-Crafts ring closure similar to 
that used in prior aphanorphine syntheses described in Section 4.2.3 As shown in Scheme 
4-11, we envisioned that a catalyst-controlled asymmetric Pd-catalyzed carboamination 
reaction of racemic substrate IV-60 could be used to set the C2 stereocenter of 
pyrrolidines IV-59a-b, thereby providing a mixture of enantioenriched diastereomers. 
This mixture of diastereomers would then be converted to one product IV-57 in a Friedel-
Crafts alkylation reaction, which would proceed via carbocation intermediate IV-58. A 
two-step reduction and demethylation would be used to transform IV-57 to (+)-
aphanorphine. Racemic substrate IV-60 could be generated from commercially available 
N-Boc-1-amino-2-propanol IV-61 in three steps.  


































This enantioconvergent strategy has several attractive features: a) the substrate 
required for the asymmetric carboamination reaction could be prepared in a concise, 
straightforward manner; b) analogs of the natural product could potentially be generated 
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through use of different aryl halides in the carboamination step; c) either enantiomer of 
the natural product should be accessible, as the absolute stereochemistry in the 
carboamination reaction would be controlled by the ligand; and d) this general strategy 
could potentially be adapted to provide access to a broad array of fused- or bridged 
bicyclic alkaloids that contain a benzylic all-carbon quaternary stereocenter.  
4.5 Enantioselective Synthesis of (+)-Aphanorphine 
To test the feasibility of this strategy, we elected to pursue a synthesis of the non-
natural (+)-enantiomer of apahanorphine, as only a few prior studies have targeted (+)-
aphanorphine,12 and the ligand needed to generate the isomer of the natural product, (R)-
Siphos-PE, is commercially available. In order to obtain IV-57 in high enantioselectivity, 
it would be necessary to generate a 1:1 mixture of diastereomers in the asymmetric 
carboamination reaction of IV-60, as any degree of substrate control in the reaction of 
IV-60 could lead to erosion of enantiomeric purity in the final product (Scheme 4-11). 
However, prior studies in our group have illustrated that diastereoselectivities are low for 
substrates bearing homoallylic substituents. For example, treatment of IV-62 with 
catalytic Pd2(dba)3 and dpe-phos produced pyrrolidines IV-63 in low diastereoselectivity, 
presumably due to lack of A(1,3) strain and 1,3-diaxial interactions in the transition state 
(Scheme 4-12).13 To test this hypothesis, we elected to synthesize a substrates bearing 
different substituents at the homoallylic position (Me vs. OR) to study their effect on 
diastereoselectivity.  
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Scheme 4-12. Synthesis of 2,4-Disubstituted Pyrrolidines 
 
Commercially available N-Boc-1-amino-2-propanol IV-61 was oxidized to ketone 
IV-64, followed by addition of allylmagneisum bromide to afford racemic tertiary 
alcohol IV-65 in good yield. Protection of the tertiary alcohol with TMS-imidazole or 
TBS-triflate proceeded smoothly to provide aminoalkenes IV-66 and IV-67 respectively 
(Scheme 4-13). Efforts to protect sterically hindered tertiary alcohol IV-65 with other 
functional groups such as TIPS, TBDPS, Me, and Bn were unsuccessful. 
Scheme 4-13. Substrate Synthesis 
 
Treatment of γ-amino alkenes IV-66 and IV-67 with Pd(OAc)2 and dpe-phos 
provided 2,4-disubstituted pyrrolidines in moderate yields and low diastereoselectivity 
(Scheme 4-14). Not surprisingly, the similarity in size of the homoallylic group in IV-68 
(methyl vs. OTMS), suggested there would be little substrate bias toward either 
diastereomer (1:1 dr). Subjecting TBS-protected γ-amino alkene IV-67 under the reaction 
conditions provided pyrrolidine IV-69 with a slight preference for one diastereomer 
(1.4:1 dr). Therefore, we elected to use TMS-protected γ-amino alkene IV-66, since the 
substrate should have little effect on asymmetric induction in Pd-catalyzed 
carboamination reaction step.  
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Scheme 4-14. Diastereoselectivity Study  
 
The coupling reaction between IV-66 and 4-bromoanisole was examined using our 
previously reported conditions for enantioselective alkene carboamination reactions 
(Scheme 4-15). After slight optimization of reaction conditions, the transformation 
afforded a 1:1 mixture of diastereomers IV-68a and IV-68b in 75% yield. In our prior 
studies, we found that optimal results were achieved with substrate concentrations of 0.2 
M. However, increased yields were obtained in reactions using 0.33 M concentration or 
higher. The higher concentration presumably increased the rate of carboamination versus 
substrate decomposition. We initially sought to separate the diastereomers and assay each 
individually to determine enantiomeric purity. Unfortunately, separation of the isomers 
was not possible. In addition, routes to prepare racemic samples of each diastereomer 
appeared to be cumbersome. As such, we elected to transform the mixture of isomers IV-
68a-b to known compound IV-71, which we could then assay for enantiomeric purity.3a 
To this end, treatment of IV-68a-b with TFA led to cleavage of both the N-Boc and O-
TMS groups, and tosylation of the resulting pyrrolidine derivative provided IV-70a-b in 
83% yield (1:1 dr) over two steps. The enantioconvergent intramolecular Friedel-Crafts 
alkylation of the mixture of diastereomers IV-70a-b provided IV-71 in 63% yield, and 
analysis by chiral HPLC indicated the molecule had been formed with 81% ee. 
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Scheme 4-15. Synthesis of (+)-Aphanorphine Intermediate IV-71 
 
With a concise route to enantiomerically enriched diastereomers IV-68a-b in 
hand, we sought to complete the synthesis of (+)-aphanorphine. We envisioned that an 
enantioconvergent Friedel-Crafts alkylation of IV-68a-b should provide IV-57, which 
could be transformed to the target in two steps (reduction and demethylation). 
Unfortunately, the Friedel-Crafts alkylation proved to be problematic (Scheme 4-16). A 
variety of conditions were surveyed for reactions of IV-68a-b and desilylated analogs 
IV-72a-b, but all of the conditions examined provided low yields of the desired product 
IV-57. Competing cleavage of the N-Boc group was frequently observed, along with 
formation of unidentifiable side products. 
Scheme 4-16. Enantioconvergent Friedel-Crafts Alkylation  
 
Although the conversion of IV-68a-b to IV-57 was not successful, N-tosylated 
derivative IV-71 has previously served as an intermediate in Zhai’s syntheses of 
aphanorphine.3a Thus, after some modification of literature procedures, IV-71 was 
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transformed to IV-73 in 64% yield via cleavage of the N-tosyl group with Red-Al 
followed by N-methylation under Eschweiler-Clarke conditions (Scheme 4-17). After 
quenching of the excess Red-Al, it was imperative to filter the crude mixture through a 
pad of celite before proceeding onto the N-methylation step. Any aluminium byproducts 
decreased yields in the subsequent N-methylation step. Although BBr3-mediated aryl 
ether cleavage of IV-73 has previously been a key feature of prior syntheses,2-4 this step 
proved to be quite challenging. Many of the described approaches to aphanorphine are 
formal syntheses, which stop prior to the challenging and selective O-demethylation step.  
Scheme 4-17. Deprotection/N-Methylation 
 
Initial attempts to O-demethylate IV-73 with 2 equivalents of BBr3 resulted in 
demethylation of both the aryl methyl ether and N-methyl substituent to afford IV-74 
(Scheme 4-18).2a Rather perplexed, we sought to run a variety of optimization studies. 
When the reaction was conducted at lowered temperatures (-78 °C and -30 °C), only 
starting material was observed. Reducing the amount of BBr3 (1 equivalent) used in the 
reaction led to recovered starting material. From our results, it seemed that this 
challenging demethylation step was temperature sensitive.   
Scheme 4-18. Initial Attempts at BBr3-Mediated Demethylation 
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However, after some experimentation and correspondence with Professor 
Raymond Funk, we found that the conditions reported by Funk provided satisfactory 
results.14 With careful control of the reaction temperature, and gradual warming from –30 
°C to 0 °C in 10 °C increments over the course of 2 h, we were able to effect the 
conversion of IV-73 to (+)-aphanorphine in 63% yield (Scheme 4-19). 
Scheme 4-19. Completion of the Synthesis 
 
4.6 Summary and Future Directions 
We have developed a concise synthesis of (+)-aphanorphine that affords the target 
molecule in 10 steps and 13% overall yield from commercially available starting 
materials. Importantly, this synthesis demonstrates the viability of a new, 
enantioconvergent strategy for the construction of benzomorphan-type alkaloids. Our 
synthesis of (+)-aphanorphine facilitates the formation of two C–C bonds, one C–N bond, 
and two rings and converts a readily available racemic substrate to an enantiomerically 
enriched product. A benzylic quaternary stereocenter is generated during the 
enantioconvergent C–C bond-forming step, and the product is formed with a synthetically 
useful level of stereocontrol. Further studies include expansion of the asymmetric 
carboamination/Friedel-Crafts alkylation sequence toward the synthesis of other 





All reactions were carried out under a nitrogen atmosphere in flame-dried 
glassware. Tris(dibenzylideneacetone)dipalladium and (R)-Siphos-PE were purchased 
from Strem Chemical Co. and used without further purification. All reagents were 
obtained from commercial sources and were used as obtained. Toluene, THF, methylene 
chloride and diethyl ether were purified using a GlassContour solvent purification 
system. The yields reported in the Supporting Information describe the result of a single 
experiment, whereas the yields reported in Scheme 4-13, Scheme 4-15, Scheme 4-17 and 
Scheme 4-19 are average yields of two or more experiments. Thus, the yields reported in 
the Supporting Information may differ from those shown in Scheme 4-13, Scheme 4-15, 
Scheme 4-17 and Scheme 4-19.  
 
Experimental Procedures and Compound Characterization Data. 
 
 
tert-Butyl (2-oxopropyl)carbamate (IV-64).15 A flame-dried flask was cooled under a 
stream of nitrogen and charged with pyridinium chlorochromate (12.3 g, 57 mmol) and 
CH2Cl2 (50 mL). The flask was cooled in an ice-water bath and (±)-tert-butyl (2-
hydroxypropyl)carbamate (5.0 g in 10 mL CH2Cl2, 28.5 mmol) was added to the solution.  
The resulting mixture was stirred overnight at rt, then Et2O (100 mL) was added. The 
resulting black tar was filtered through a plug of silica gel and concentrated. The crude 
product was purified by flash chromatography on silica gel to afford 4.7 g (96%) of the 
title compound as a yellow oil. Spectroscopic properties were consistent with those 
reported in the literature.15  1H NMR (400 MHz, CDCl3) δ 5.21 (s, br, 1 H), 4.03 (d, J = 
4.5 Hz, 2 H), 2.18 (s, 3 H), 1.44 (s, 9 H). 
 
 
(±)-tert-Butyl (2-hydroxy-2-methylpent-4-en-1-yl)carbamate (IV-65).  A flame-dried 
flask was cooled under a stream of nitrogen and charged with a solution of 
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allylmagnesium bromide (92 mL, 1 M in Et2O) and additional Et2O (25 mL). The 
resulting solution was cooled in an ice-water bath and a solution of tert-butyl (2-
oxopropyl)carbamate (8.0 g, 46 mmol) in Et2O (25 mL) was added slowly via syringe. 
The resulting mixture was warmed to rt and stirred until the starting material was 
consumed as judged by TLC analysis (ca. 1.5 h). The mixture was then cooled in an ice-
water bath and the reaction was quenched by the slow addition of water (100 mL). The 
mixture was transferred to a separatory funnel and the layers were separated. The 
aqueous layer was extracted with Et2O (2 x 100 mL), and the combined organic layers 
were dried over anhydrous Na2SO4, filtered, and concentrated to afford 9.3 g (94%) of 
the title compound as a brown oil that was used without further purification. 1H NMR 
(500 MHz, CDCl3) δ 5.95–5.81 (m, 1 H), 5.21–5.07 (m, 2 H), 4.90 (s, br, 1 H), 3.13 (d, J 
= 6.2 Hz, 2 H), 2.40 (s, 1 H), 2.23 (d, J = 7.4 Hz, 2 H), 1.45 (s, 9 H), 1.16 (s, 3 H); 13C 
NMR (125 MHz, CDCl3) δ 156.7, 133.4, 118.3, 79.1, 72.2, 49.6, 44.2, 28.1, 24.1; IR 




(±)-tert-Butyl {2-methyl-2-[(trimethylsilyl)oxy]pent-4-en-1-yl}carbamate (IV-66). A 
flame-dried flask equipped with a stirbar was cooled under a stream of nitrogen and 
charged with (±)-tert-butyl (2-hydroxy-2-methylpent-4-en-1-yl)carbamate (5.0 g, 23 
mmol). Neat 1-(trimethylsilyl)-1H-imidazole (6.8 mL, 46 mmol) was added and the 
resulting mixture was stirred at rt until the starting material had been consumed as judged 
by TLC analysis (ca. 4 h). Water (10 mL) was added and the resulting mixture was 
extracted with CH2Cl2 (4 x 20 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by flash 
chromatography on silica gel to afford 6.0 g (90%) of the title compound as a pale yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 5.87–5.73 (m, 1 H), 5.09–5.01 (m, 2 H), 4.74 (s, br, 1 
H), 3.16–2.99 (m, 2 H), 2.23 (d, J = 7.2 Hz, 2 H), 1.45 (s, 9 H), 1.19 (s, 3 H), 0.13 (s, 9 
H). 13C NMR (100 MHz, CDCl3) δ 156.1, 133.9, 117.9, 79.0, 75.7, 50.0, 45.2, 28.3, 24.9, 






(IV-67). A flame-dried flask was charged with (±)-tert-butyl (2-hydroxy-2-methylpent-4-
en-1-yl)carbamate (0.3 g, 1.4 mmol) and CH2Cl2 (1.5 mL). The solution was cooled to 0 
°C and 2,6-lutidine (0.5 mL, 2.2 mmol) was added dropwise followed by dropwise 
addition of neat TBSOTf (0.5 mL, 7 mmol). The resulting mixture was stirred at 0 °C for 
30 min, then quenched with water. The mixture was transferred to a separatory funnel, 
the layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). 
The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated. The crude product was purified by flash chromatography on silica gel to 
afford 0.35 g (76%) of the title compound as a pale yellow oil. 1H NMR (500 MHz, 
CDCl3) δ 5.86–5.74 (m, 1 H), 5.08–5.00 (m, 2 H), 4.70 (s, 1 H), 3.16–3.00 (m, 2 H), 2.23 
(d, J = 9.5 Hz, 2 H), 1.44 (s, 9 H), 1.18 (s, 3 H), 0.87 (s, 9 H), 0.1 (s, 6 H); 13C NMR (100 
MHz, CDCl3) 156.1, 134.0, 117.9, 79.0, 75.4, 50.0, 43.3, 28.4, 25.8, 25.0, 18.1, –2.1; IR 





pyrrolidine-1-carboxylate (IV-68a-b). A flame-dried Schlenk tube was cooled under a 
stream of nitrogen and charged with Pd2(dba)3 (191 mg, 0.2 mmol), (R)-Siphos-PE (303 
mg, 0.06 mmol) and NaOtBu (960 mg, 0.5 mmol). The tube was evacuated and 
backfilled with nitrogen three times, then a solution of (±)-tert-butyl {2-methyl-2-
[(trimethylsilyl)oxy]pent-4-en-1-yl}carbamate IV-66 (3.0 g, 10 mmol) and 4-
bromoanisole (3.74 g, 20 mmol) in toluene (30 mL) was added via syringe. The resulting 
mixture was stirred at rt for 1 min then was immersed in 90 °C oil bath and stirred 
overnight (ca. 14 h). The mixture was then cooled to room temperature and saturated 
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aqueous ammonium chloride (10 mL) was added. The mixture was transferred to a 
separatory funnel, the layers were separated, and the aqueous layer was extracted with 
EtOAc (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered, and concentrated. The crude product was purified by flash chromatography on 
silica gel to afford 3.1 g (75%) of the title compound as a pale yellow oil. The product 
was judged to be a 1:1 mixture of rotamers and a 1:1 mixture of diastereomers by 1H 
NMR analysis. Data are for the mixture. [α]23D +18.4 (c 1.0, CH2Cl2); 1H NMR (400 
MHz, CDCl3) δ 7.17–7.03 (m, 2 H), 6.86–6.78 (m, 2 H), 4.19–3.82 (m, 1 H), 3.79 (s, 3 
H), 3.76–3.10 (m, 2 H), 2.93–2.54 (m, 2 H), 1.94–1.79 (m, 1 H), 1.77–1.66 (m, 1 H), 
1.55–1.47 (m, 9 H), 1.33–1.26 (m, 3 H), 0.14 (s, 4.5 H), 0.07 (s, 4.5 H); 13C NMR (100 
MHz, CDCl3) δ 157.8, 157.7, 154.9, 154.7, 154.3, 130.8, 130.5, 130.3, 130.2, 130.0, 
126.5, 113.6, 113.5, 113.4, 113.3, 79.0, 78.9, 78.8, 78.6, 78.0, 77.8, 77.6, 59.9, 59.7, 59.1, 
59.0, 58.8, 58.2, 57.9, 54.7, 46.6, 45.5, 44.5, 43.4, 39.6, 39.4, 38.3, 38.2, 28.3, 28.1, 28.0, 
26.6, 26.5, 24.8, 24.7, 2.2, 1.9, 1.8, 1.7; IR (film) 2972, 1699, 1684 cm-1; MS (ESI): 




methylpyrrolidine-1-carboxylate (IV-69). The title compound was prepared from (±)-
tert-butyl {2-[(tert-butyldimethylsilyl)oxy]-2-methylpent-4-en-1-yl}carbamate IV-67 
(1.5 g, 4.6 mmol) using a procedure analogous to that described for the synthesis of IV-
68a-b except that Pd(OAc)2 (20.7 mg, 0.09 mmol) was employed as the palladium 
source, and Dpe-phos (99 mg, 0.184 mmol) was used as ligand. This procedure afforded 
1.24 g (62 %) of the title compound as a pale yellow oil. The product was judged to be a 
~1:1 mixture of rotamers and a ~1.4:1 mixture of diasteromers mixture of diastereomers 
by 1H NMR analysis. Data are for the mixture. 1H NMR (400 MHz, CDCl3) δ 7.15–7.01 
(m, 2 H), 6.85–6.76 (m, 2 H), 4.18–3.80 (m, 1 H), 3.76 (s, 3 H), 3.54–3.40 (m, 0.5 H), 
3.34–3.06 (m, 2 H), 2.87–2.75 (m, 1 H), 2.74–2.57 (m, 0.5 H), 1.88–1.68 (m, 2 H), 1.58–
1.42 (m, 9 H), 1.30–1.22 (m, 3 H), 0.960.78 (m, 9 H), 0.08–0.01 (m, 6 H); 13C NMR 
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(100 MHz, CDCl3) δ 158.0, 154.6, 131.1, 130.6, 130.3, 113.8, 113.7, 113.6, 113.5, 79.4, 
79.2, 78.9, 77.8, 77.6, 60.3, 59.7, 59.5, 59.0, 58.9, 58.7, 58.4, 58.1, 55.1, 55.0, 46.7, 45.6, 
45.2, 44.2, 39.8, 39.7, 38.5, 38.4, 28.5, 28.3, 267.2, 27.0, 25.7, 25.6, 24.8, 24.6, 17.9, 
17.8, -2.5, -2.7, -2.9; IR (film) 2931, 1696 cm-1; MS (ESI): 458.2703 (458.2697 calcd for 
C24H41NO4Si, M + Na+). 
 
 
(+)-(5S,3RS)-5-(4-Methoxybenzyl)-3-methyl-1-tosylpyrrolidin-3-ol (IV-70a-b).3a A 
round-bottom flask equipped with a stirbar was charged with (+)-(2S,4RS)-tert-Butyl 2-
(4-methoxybenzyl)-4-methyl-4-[(trimethylsilyl)oxy]pyrrolidine-1-carboxylate and 
CH2Cl2 (7.6 mL). The resulting solution was cooled to 0 °C, trifluoroacetic acid (5.7 mL, 
76.2 mmol) was added, and the solution was warmed to rt and stirred until the starting 
material had been consumed as judged by TLC analysis (ca. 10 min). The reaction 
mixture was diluted with water, basified with NH4OH, and transferred to a separatory 
funnel. The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 
50 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated. The crude product was dissolved in THF (5 mL) and the resulting solution 
was added to a stirring solution of triethylamine (3.2 mL, 22.9 mmol), tosyl chloride 
(2.18 mg, 11.4 mmol) and THF (10 mL). The reaction mixture was stirred overnight at rt, 
then saturated NaHCO3 (10 mL) was added. The mixture was transferred to a separatory 
funnel and extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by 
flash chromatography on silica gel to afford 2.3 g (80%) of the title compound as a 
colorless oil.3a The product was judged to be a 1:1 mixture of diastereomers by 1H NMR 
analysis. Data are for the mixture. [α]23D +65.7 (c 1.0, CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ 7.82–7.73 (m, 2 H), 7.36–7.30 (m, 2 H), 7.20 (d, J = 8.0 Hz, 1.2 H), 7.14 (d, J = 
8.4 Hz, 0.8 H), 6.88–6.80 (m, 2 H), 4.02–3.94 (m, 0.5 H), 3.83–3.75 (m, 3.5 H), 3.42–
3.37 (m, 1 H), 3.30–3.21 (m, 1 H), 3.18–3.07 (m, 1 H), 3.03 (d, J = 10.4 Hz, 0.6 H), 2.83 
(dd, J = 9.2, 13.6 Hz, 0.4 H), 2.44–2.41 (m, 3 H), 1.84–1.74 (m, 1 H), 1.64–1.54 (m, 2 
 110
H), 1.19 (m, 1 H), 1.09 (s, 2 H); 13C NMR (100 MHz, CDCl3) δ 158.3, 143.7, 143.6, 
133.9, 130.9, 130.6, 130.0, 129.8, 129.7, 129.6, 127.8, 127.7, 113.9, 113.7, 76.1, 76.0, 
61.7, 61.6, 61.5, 61.0, 55.2, 45.5, 43.2, 41.1, 41.0, 25.4, 24.1, 21.5 (5 peaks are 




benzo[d]azepine (IV-71).3a A flame-dried round-bottom flask was charged with 
aluminum trichloride (8.0 g, 60 mmol) and CH2Cl2 (100 mL). The flask was cooled to 0 
°C and a solution of (+)-(5S,3RS)-5-(4-methoxybenzyl)-3-methyl-1-tosylpyrrolidin-3-ol 
(2.15 g, 5.7 mmol) in CH2Cl2 (20 mL) was added via syringe. The resulting mixture was 
allowed to slowly warm to rt and was stirred overnight. The reaction mixture was then 
poured into a solution of saturated aqueous NaHCO3 (50 mL). The mixture was 
transferred to a separatory funnel, the layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by flash 
chromatography on silica gel to afford 1.2 g (60%) of the title compound as a pale yellow 
solid. The enantiomeric excess was determined to be 81% ee by chiral HPLC analysis 
(Chiralpak AD-H 0.46 cm x 25 cm, 1 % iPrOH/hexanes, 1 mL/min, λ = 254 nm, RT = 
8.0 and 9.8 min). Spectroscopic properties were consistent with those previously reported 
in the literature. [α]23D +16.0 (c 1.0, CH2Cl2) [for ent-IV-71 lit.3a [α]27D –16.9 (c 0.89, 
CHCl3)]; mp: 137–140 °C (lit.3a mp 136–138 °C); 1H NMR (400 MHz, CDCl3) δ 7.70 (d, 
J = 8.4 Hz, 2 H), 7.28 (d, J = 8.0 Hz, 2 H), 6.97 (d, J = 8.4 Hz, 1 H), 6.78 (d, J = 2.5 Hz, 
1 H), 6.72 (dd, J = 2.6, 8.3 Hz, 1 H), 4.41–4.35 (m, 1 H), 3.78 (s, 3 H), 3.40 (dd, J = 1.2, 
8.7 Hz, 1 H), 3.11 (d, J = 16.6 Hz, 1 H), 3.02 (d, J = 8.6 Hz, 1 H), 2.93 (dd, J = 2.8, 16.5 





carboxylate (IV-72a-b). A round-bottom flask was charged with (+)-(2S,4RS)-tert-butyl 
2-(4-methoxybenzyl)-4-methyl-4-[(trimethylsilyl)oxy]pyrrolidine-1-carboxylate (100 mg, 
0.254 mmol) and tetrabutylammonium fluoride (0.51 mL, 0.51 mmol) 1 M solution in 
THF) and the resulting solution was stirred until the starting material had been consumed 
as judged by TLC analysis (ca. 1 h). The reaction mixture was diluted with water (5 mL) 
and CH2Cl2 (5 mL) then was transferred to a separatory funnel. The layers were 
separated, and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). The combined 
organic layers were dried over anhydrous Na2SO4 and concentrated. The crude product 
was purified by flash chromatography on silica gel to afford 73 mg (90%) of the title 
compound as a colorless viscous oil. The product was judged to be a 1:1 mixture of 
rotamers and a 1:1 mixture of diastereomers by 1H NMR analysis. Data are for the 
mixture. [α]23D +23.0 (c 1.0, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.18–7.02 (m, 2 H), 
6.84–6.78 (m, 2 H), 4.24–3.88 (m, 1 H), 3.79 (s, 3 H), 3.70–3.08 (m, 2.5 H), 3.00–2.60 
(m, 1.5 H), 1.96–1.70 (m, 2 H), 1.51 (s, 9 H), 1.38–1.24 (m, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 157.9, 155.1, 154.6, 131.1, 130.4, 130.1, 113.7, 79.4, 77.2, 76.1, 75.7, 75.2, 
59.9, 59.5, 59.3, 58.2, 57.7, 55.0, 45.1, 44.5, 43.0, 42.5, 39.7, 39.5, 38.5, 38.1, 28.5, 26.7, 





(S1). A flame-dried round-bottom flask was charged with (+)-(1S,4S)-8-methoxy-1-
methyl-3-tosyl-2,3,4,5-tetrahydro-1H-1,4-methanobenzo[d]azepine (1.1 g, 3.1 mmol) and 
xylene (15 mL). A solution of Red-Al was added (3.5 M in toluene, 3.3 mL, 11.4 mmol) 
and the mixture was heated to reflux for 1 h. The solution was cooled to 0 °C, diluted 
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with ether and quenched with a few drops of water. The solution was filtered through a 
pad of celite and concentrated in vacuo. The crude product was purified by flash 
chromatography on silica gel to afford 450 mg (71%) of the title compound as a yellow 
oil.  [α]23D +38.2 (c 1.0, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.02 (d, J = 8.5 Hz, 1 
H), 6.82 (d, J = 2.5 Hz, 1 H), 6.71 (dd, J = 3.0, 8.5 Hz, 1 H), 3.85–3.79 (m, 4 H), 3.11–
3.02 (m, 2 H), 2.92 (d, J = 10 Hz, 1 H), 2.78 (m, 2 H), 1.96–1.92 (m, 1 H), 1.86 (d, J = 11 
Hz, 1 H), 1.49 (s, 3 H). 
 
 
(–)-8-O-methylaphanorphine (IV-73). A flame-dried round-bottom flask was charged 
with (+)-(1S,4S)-8-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-1,4-
methanobenzo[d]azepine (300 mg, 1.5 mmol), a solution of 37% aqueous formalin (1.8 
mL) and formic acid (2.8 mL). The reaction mixture was heated to 100 °C for 1.5 h, then 
cooled to rt, diluted with water (10 mL), and basified with 10% NaOH solution. The 
mixture was transferred to a separatory funnel and extracted with CH2Cl2 (3 x 20 mL). 
The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated in vacuo. The crude product was purified by flash chromatography on silica 
gel to afford 294 mg (90%) of the title compound as a pale yellow oil.  Spectroscopic 
properties are consistent with those previously reported in the literature. [α]23D –5.8 (c 
1.0, CHCl3), [lit.12a [α]27D –7.4 (c 0.35, CHCl3)]; 1H NMR (400 MHz, CDCl3) δ 7.02 (d, J 
= 8.4 Hz, 1 H), 6.78 (d, J = 2.8 Hz, 1 H), 6.68 (dd, J = 2.8, 8.4 Hz, 1 H), 3.78 (s, 3 H), 
3.42 (m, 1 H), 3.02 (d, J = 16.4 Hz, 1 H), 2.88–2.84 (m, 2 H), 2.82 (d, J = 1.2 Hz, 1 H), 
2.76 (d, J = 9.2 Hz, 1 H), 2.48 (s, 3 H), 2.02 (ddd, J = 1.2, 5.6, 10.8 Hz, 1 H), 1.48 (s, 3 





Attempts to demethylate (–)-8-O-methylaphanorphine IV-73 according to a reported 
procedure by Takano resulted in formation of undesired product IV-74.12a 1H NMR (500 
MHz, CD3OD) δ 7.00 (d, J = 8.0 Hz, 1 H), 6.80 (s, 1 H), 6.726.68 (m, 1 H), 4.094.03 
(m, 1 H), 3.323.17 (m, 7 H), 2.18 (d, J = 12.0 Hz, 1 H), 1.53 (s, 3 H); 13C NMR (125 







(+)-aphanorphine (IV-1). Demethylation of (–)-8-O-methylaphanorphine was carried 
according to reported procedure.14 A flame-dried round-bottom flask was charged with 
IV-73 (40 mg, 0.18 mmol) and CH2Cl2 (1 mL) and cooled to –30 ˚C. BBr3 (1.0 M in 
CH2Cl2, 0.36 mL) was added slowly dropwise. The reaction mixture was stirred for 30 
min at –30 ˚C, 30 min at –20 ˚C, 30 min at –10 ˚C and then 30 min at 0 ˚C. The reaction 
was quenched at 0 °C with aqueous NaHCO3 and extracted with CH2Cl2 (3 x 5 mL). The 
combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. The resulting residue was taken up in 2 mL of 3 M NaOH and heated at 100 °C 
for 5 min. The solution was acidified with 1 M HCl and basified with saturated aqueous 
NaHCO3. The aqueous layer was extracted with CH2Cl2 (3 x 10 mL), dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude solid was triturated 
with acetone to afford 23 mg (63%) of the title compound as a white solid. Spectroscopic 
properties are consistent with the present literature. [α]23D +28.0 (c 0.1, MeOH) [lit.12a 
[α]27D +37.5 (c 0.16, MeOH)]; mp 202–208 °C (lit.12a mp 215–222). 1H NMR (400 MHz, 
CD3OD) δ 6.89 (d, J = 8 Hz, 1 H), δ 6.67 (d, J = 2.4 Hz, 1 H), δ 6.56 (dd, J = 2.4, 8.4 Hz, 
1 H), 3.38 (m, 1 H), 2.97 (d, J = 16.8 Hz, 1 H), 2.85 (m, 2 H), 2.63 (d, J = 9.6 Hz, 1 H), 
2.40 (s, 3 H), 2.01 (q, J = 5.6 Hz, 1 H), 1.83 (d, J = 11.2 Hz, 1 H), 1.44 (s, 3 H); 13C 
 114
NMR (100 MHz, CD3OD) δ 156.6, 148.6, 131.2, 125.2, 114.5, 110.9, 72.7, 63.4, 44.3, 
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Chapter 5 
Preliminary Studies on Asymmetric Pd-Catalyzed Reactions for the Synthesis of 
Other 5-Membered Heterocycles 
5.1 Introduction  
5-membered heterocycles such as imidazolidin-2-ones, isoxazolidines, 
pyrazolidines, and tetrahydrofurans are important motifs found in a wide array of 
molecules that possess interesting biological activities.1 This chapter describes our 
preliminary studies on asymmetric Pd-catalyzed alkene functionalization reactions for the 
synthesis of imidazolidin-2-ones, isoxazolidines, pyrazolidines, and tetrahydrofurans, 
which builds on the study of enantioselective pyrrolidine synthesis described in Chapter 
2. We have identified some promising ligand scaffolds for these transformations and 
promising leads will be followed up by future group members.   
5.2 Enantioselective Synthesis of Imidazolidin-2-ones 
5.21 Biological Importance 
 The imidazolidin-2-one core is an important scaffold in pharmaceutical and 
medicinal chemistry. Cyclic ureas have been demonstrated to act as potent HIV protease 
inhibitors,2 5-HT3 receptor antagonists,3 NK1 antagonists,4 and chiral auxiliaries.5 For 
example, imidazolidin-2-one V-1 has been implicated as a potential HIV protease 
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inhibitor and imidazolidin-2-one V-2 has been demonstrated to act as a potent Neurokinin 
antagonist (Figure 5-1).2,4  
Figure 5-1. Biologically Important Imidazolidin-2-ones 
 
5.22 Asymmetric Methods for the Synthesis of Imidazolidin-2-ones 
 Imidazolidin-2-ones are generally prepared by carbonylation of chiral 1,2-
diamines with phosgene or phosgene derivatives.6 As shown in Scheme 5-1, BOC-
alanine N-hydroxysuccinimide ester V-3 is condensed with benzylamine to provide 
amide V-4. TFA deprotection, amide reduction and subsequent cyclization with 
triphosgene provide cyclic urea V-5 in 60% over 3 steps. However, the preparation of 
chiral 1,2-diamines often requires several steps.7 
Scheme 5-1. Cyclization of 1,2-Diamines with Triphosgene 
 
 An alternative method for the synthesis of chiral imidazolidin-2-ones involves 
intramolecular SN2 reactions of substrates based on N-(2-hydroxyethyl)urea V-7 (Scheme 
5-2). Treatment of enantioenriched 1,2-amino alcohol V-6 with phenylisocyanate 
generates acyclic urea V-7, which upon exposure to TsCl and t-BuOK, facilitates 
cyclization to yield imidazolidin-2-one V-8. However, this method requires the synthesis 
of chiral 1,2-amino alcohol substrates. 
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Scheme 5-2. One-Pot Synthesis of Imidazolidin-2-ones  
 
 As previously discussed in Chapter 1, an asymmetric catalytic approach toward 
the synthesis of imidazolidin-2-ones was developed by Shi,8 where treatment of 
conjugated dienes (V-9) and di-tert-butylazirdinone (V-10) with Pd2(dba)3 and 
tetramethylpiperidine-derived phosphoramidite V-L* afforded cyclic ureas V-11 in good 
yield and high enantioselectivity (Scheme 5-3). The reaction is believed to proceed 
through oxidative addition of Pd(0) to V-10, followed by syn-aminopalladation and 
reductive elimination to yield V-11.8c   
Scheme 5-3. Asymmetric Pd-Catalyzed Diamination Reaction 
 
5.23 Project Goals and Previous Work 
We sought to develop a method where readily accessible achiral starting material 
such as V-12 could be coupled with aryl or alkenyl halide to provide chiral imidazolidin-
2-one V-13 via asymmetric Pd-catalyzed carboamination reactions (Scheme 5-4). This 
method would be amenable toward analog synthesis of V-13, which may be cleaved to 
provide functionalized chiral 1,2-diamines V-14. 
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Scheme 5-4. Synthetic Strategy 
 
  Dr. Jonathan Fritz, a former graduate student in our group, developed a method 
which enabled the construction of racemic imidazolidin-2-ones V-13 via Pd-catalyzed 
carboamination reactions between N-allylureas V-12 and aryl bromides.9 As shown in 
Scheme 5-5, Dr. Fritz also examined an asymmetric variant of this reaction for the 
coupling of V-12a and 2-bromotoluene. After a brief ligand screen, he discovered that a 
catalyst system of Pd2(dba)3 and (S)-Phanephos provided cyclic urea V-13a in 86% yield 
and 32% ee.10  





1 mol % Pd2(dba)3
2 mol % (S)-Phanephos NN
O
Bn
NaOtBu, Toluene, 110 °C
PMP









5.24 Ligand Screen 
We decided to examine the coupling of V-12a and 2-bromonaphthalene with 
catalytic Pd2(dba)3 and other chiral phosphine ligands (Table 5-1). 2-bromonaphthalene 
was used in place of 2-bromotoluene to minimize the influence of aryl halide steric 
properties on the aminopalladation step. Bis-phosphine ligand V-L2 was found to be a 
promising lead, yielding V-13b in 60% yield and 45% ee. However, most bidentate and 
monodentate phosphine ligands effected the formation of V-13b in relatively low ee.  
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Table 5-1. Phosphine Ligand Screena,b,c 
 
 As shown below, chiral phosphite ligands were screened for the coupling of V-
12a and 2-bromonaphthalene (Table 5-2).11 A phosphite ligand derived from 
cinchonidine (V-L13) provided promising enantioselectivities (65% ee). Other ligands 
derived from chiral alcohols such as menthol (V-L9), and 2-phenylcyclohexanol (V-L10) 
provided low yields and ee. In comparison to the other phosphite ligands screened, it 
seems that the cinchonidine alkaloid is important for selectivity and may provide a 




Table 5-2. Phosphite Ligand Screena,b,c 
2 mol % Pd2(dba)3
6 mol % Ligand
NaOtBu, Toluene, 90 °C
Br
+
a Conditions: Reactions were conducted on a 0.20 mmol scale with 1.0 equiv substrate, 2.0 equiv 2-
bromonaphthalene, 2.0 equiv NaOtBu, 2 mol % Pd2(dba)3, 6 mol % ligand, toluene (0.2 M), 90 °C, 12-15 h. b
Enantiomeric excess was determined by chiral HPLC analysis. c Negative ee values indicate the major

























































18% yield, 0% ee
V-L12











26% yield, 24% ee
 
 Several phosphoramidites were examined to determine their effect on 
enantioselectivity. As shown in Table 5-3, phosphoramidite ligands V-L18, V-L20, and 
V-L21 provided good yields and promising enantioselectivities (up to 58% ee) of V-13b. 
Phosphoramidite ligands that contained (+)-bis[(R)-1-phenethyl]amine were important 
for enantioselectivity, as phosphoramidite ligand V-L14 and V-L19 failed to provide any 
selectivity (0% ee). In addition, substitution at the 3 and 3’ positions of the BINOL 
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backbone decreased enantioselectivity (V-L17). It seems that there is matched pair for 
chiral ligand (S)-Siphos-PE (V-L21), which provided V-13b in higher ee in comparison 
to (R)-Siphos-PE. Also, a partially hydrogenated diol backbone (V-L18, V-L21) seems to 
be important for higher enantioselectivities.  
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Table 5-3. Phosphoramidite Ligand Screena,b,c 
 
 We also decided to examine the coupling of different acyclic urea substrates (V-
12b, V-12c) and 2-bromonaphthalene in the presence of Pd2(dba)3 and (R)-Siphos-PE 
(Scheme 5-6). The coupling proved ineffective, as these substrates provided no desired 
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product under the reaction conditions. Previous control experiments have demonstrated 
that base-mediated substrate decomposition to the corresponding N-allyl amine may 
occur and be responsible for low reaction conversions.9b 
Scheme 5-6. Effect of Substrate on Enantioselectivity 
 
5.25 Summary and Future Directions 
 In summary, we have identified bidentate phosphine (V-L2), monodentate 
phosphite (V-L13), and phosphoramidite (V-L21) ligands as potential scaffolds for the 
enantioselective synthesis of 4-substituted imidazolidin-2-ones. It is unique that three 
different types of ligands provide promising enantioselectivities for these reactions. We 
have also discovered that N-aryl substituted substrates are necessary for reactivity and 
selectivity. Further studies will include the synthesis of closely related ligands to examine 
factors that dictate selectivity (Figure 5-2).    
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Figure 5-2. Other Potential Chiral Ligand Analogs 
 
5.3 Enantioselective Synthesis of Isoxazolidines 
5.31 Biological Importance 
Isoxazolidines are important synthetic intermediates for various natural 
products,12 and are core structures in biologically active compounds such as Pyrinodemin 
A (V-15),13a PR968-234FB (V-16),13b and V-17 (Figure 5-3).13c These compounds 
exhibit cytotoxicity, anti-fungal activity, and can serve as transcriptional activators 
respectively.13 In addition, the NO bond can be cleaved to afford synthetically useful 
chiral 1,3-amino alcohols.14 
Figure 5-3. Biologically Active Isoxazolidines  
 
5.32 Asymmetric Methods for the Synthesis of Isoxazolidines  
One of the most common methods employed for the asymmetric synthesis of 
isoxazolidines are 1,3-dipolar cycloaddition reactions between nitrones and alkenes.15 
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These 1,3-dipolar cycloaddition reactions can be catalyzed by transition metal or 
organocatalysts.16 For example, Maruoka describes an asymmetric 1,3-dipolar 
cycloaddition reaction catalyzed by chiral bis-Ti(IV) oxide (S,S)-V-L22, which provides 
isoxazolidines in excellent diastereo- and enantiocontrol (Scheme 5-7). However, 
substrate scope is often limited to specific olefin substrates, which predominately afford 
the stereoisomer resulting from endo addition to the alkene.  
Scheme 5-7. Chiral Lewis Acid Catalyzed 1,3-Dipolar Cycloaddition  
 
5.33 Project Goals and Previous Work 
In our group, we have previously developed a stereoselective synthesis of 
isoxazolidines through Pd-catalyzed carboetherification and carboamination reactions of 
N-butenylhydroxylamines.17 As shown below, our goal is to develop an asymmetric 
variant for the coupling of N-(but-3-enyl)hydroxyl amine derivatives V-20 (Scheme 5-8). 
The NO bond of isoxazolidines V-21 may be cleaved to generate chiral 1,3-amino 
alcohol V-22.  




5.34 Ligand Screen 
In our initial screen, we examined the coupling of V-20a with 2-
bromonaphthalene using Pd2(dba)3 and commercially available ligands (Table 5-4). 
Moderate yields were obtained with bis-phosphine (R)-SDP (V-L1) and phosphite ligand 
V-L10, but low enantioselectivity was observed. Phosphoramidite ligand (R)-Siphos-PE 
(V-L20), which provided high selectivities for the formation of enantioenriched 2-
substituted pyrrolidines,18 did not effect formation of V-21a. Efforts to use other 
palladium sources such as Pd(OAc)2 and weak bases such as Cs2CO3 led to low reactivity.  
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Table 5-4. Chiral Ligand Screena,b 
 
 
5.35 Summary and Future Directions 
 To this date, no chiral ligand has been identified as a primary lead for the 
asymmetric synthesis of isoxazolidines. Base-mediated substrate decomposition was 
observed in many of these reactions. Future studies will involve screening of other chiral 
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ligands and employing substrates such as V-20b or V-23 for the enantioselective 
synthesis of isoxazolidines (Scheme 5-9). Recent work in the Wolfe lab has shown that 
the cyclizing atom (N or O) can have a drastic effect on diastereoselectivity for the 
synthesis of substituted isoxazolidines.17  
Scheme 5-9. Future Ligand Screen/Other Substrates 
 
5.4 Enantioselective Synthesis of Pyrazolidines 
5.41 Biological Importance 
Pyrazolidines are core structures in biologically relevant molecules such as anti-
diabetic V-25,19 and potent neuroprotective agent FKBP12 antagonist V-26 (Figure 5-
4).20 Additionally, pyrazolidines may be oxidized to provide biologically active 
pyrazolines,21 or cleaved for the synthesis of enantioenriched 1,3-diamines, which have 
served as HIV-1 protease inhibitors.22  
Figure 5-4. Biologically Important Pyrazolidines  
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5.42 Asymmetric Methods for the Synthesis of Pyrazolidines 
A recent method for the enantioselective synthesis of pyrazolidines was described 
by Kobayashi,23 which involved chiral zirconium catalyst derived from (R)-V-L28 for the 
[3+2] cycloaddition reaction of hydrazones such as V-27 and ketene dimethyl acetal 
(Scheme 5-10). Although these reactions provided pyrazolidine products (V-28) in good 
yield and enantioselectivity, other olefins substrates such as ethyl vinyl ether led to a 
mixture of diastereomers. Leighton and coworkers were able to address this limitation by 
using a chiral silicon Lewis acid (S,S)-V-L29, which facilitated cycloaddition of 
hydrazone V-27 and ethyl vinyl ether for the synthesis of pyrazolidine V-29 in good 
yield, enantioselectivity, and diastereoselectivity (Scheme 5-10).24  
Scheme 5-10. [3+2]-Cycloaddition Reactions 
 
 Asymmetric gold-catalyzed hydroamination reactions have emerged as an 
efficient method for the synthesis of enantioenriched 2-vinyl pyrazolidines such as V-
31.25 Treatment of allene V-30 with chiral Au complex V-L30 provided V-31 in 98% 
yield and 99% ee. This method is high yielding and selective for the synthesis of 
 132
pyrazolidines, but the substrate scope is limited to homoallenic substrates shown in 
Scheme 5-11.  
Scheme 5-11. Enantioselective Au-Catalyzed Hydroamination  
 
5.43 Project Goals and Previous Work 
Our aim is to develop an asymmetric carboamination reaction that couples V-32a 
and an aryl or alkenyl halide for the formation of pyrazolidine V-33 (Scheme 5-12). The 
NN bond may be cleaved to provide synthetically useful chiral 1,3-diamines V-34.  














R1 = aryl, alkenyl
 
Preliminary work on asymmetric carboamination reactions for the synthesis of 
pyrazolidines were initially conducted by Dr. Natalie Giampietro, a former graduate 
student in the group. Of the chiral ligands screened, Dr. Giampietro typically observed 
decomposition of the starting material. One exception was the coupling of V-35 and 2-
bromonaphthlene in the presence of Pd2(dba)3 and bis-phosphine ligand (R)-BINAP, 
which provided pyrazolidine product V-36 in 48% yield, but as a racemic mixture 
(Scheme 5-13).26  
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Scheme 5-13. Preliminary Studies 
 
5.44 Ligand Screen 
A brief ligand screen was examined for the coupling of V-32a and 2-
bromonaphthalene with Pd2(dba)3 as the palladium source (Table 5-5). Bis-phosphines, 
monodentate phosphines, and phosphite ligands provided V-32a in low yield and ee. 
However, the use of Pd/(R)-Siphos-PE catalyst system afforded V-33a in moderate yield 
and ee. Base-mediated substrate decomposition was often observed in these reactions, 
which may be responsible for low yields. The non-cyclizing nitrogen may also coordinate 
to the palladium catalyst, which would lead to decreased reactivity.  
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Boc 2 mol % Pd2(dba)3
6 mol % Ligand
NaOtBu, Toluene, 90 °C
+
Br *
a Conditions: Reactions were conducted on a 0.20 mmol scale with 1.0 equiv substrate, 1.2 equiv 2-
bromonaphthalene, 2.0 equiv NaOtBu, 2 mol % Pd2(dba)3, 6 mol % ligand, toluene (0.20 M), 90 °C, 12-15 h. b
Enantiomeric excess was determined by chiral HPLC analysis. c Negative ee values indicate the major














5.45 Summary and Future Directions 
 Preliminary studies have identified (R)-Siphos-PE as a potential ligand scaffold 
for the asymmetric synthesis of pyrazolidines. The non-cyclizing nitrogen atom on V-32a 
may be coordinating to the catalyst system, which may prevent alkene insertion and lead 
to substrate decomposition. Other phosphoramidite ligands and substrates bearing 
different N-protecting groups should be examined.   
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5.5 Enantioselective Synthesis of Tetrahydrofurans 
5.51 Biological Importance 
 The tetrahydrofuran core can be found in a variety of biologically active natural 
products that possess anti-tumor, anti-viral, and anti-microbial activity.27 For example, 
simplakidine A (V-37) and annoceous acetogenin asimicin (V-38) are natural products 
that exhibit anti-cancer activity (Figure 5-5).27e,28  


























5.52 Asymmetric Methods for the Synthesis of Tetrahydrofurans 
 There have been many methods developed for the stereoselective synthesis of 
tetrahydrofurans, which involve nucleophilic substitution processes or alkene 
functionalization reactions.29 However, asymmetric variants that provide enantioenriched 
tetrahydrofurans are less common. A classical method for the asymmetric synthesis of 
tetrahydrofurans is a stereoselective nucleophilic substitution reaction of functionalized 
chiral alcohols. As shown in Scheme 5-14, Britton and coworkers have demonstrated that 
microwave heating of chlorotriols such as V-39 facilitates regioselective cyclization for 
the formation of tetrasubstituted tetrahydrofuran (+)-Goniothalesdiol (V-40).30 The 
reaction is high yielding, regioselective and does not require protecting group 
manipulations, but the synthesis of the chlorotriol substrates can be lengthy.  
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Scheme 5-14. Synthesis of (+)-Goniothalesdiol 
 
 Kang and coworkers reported a catalytic enantioselective iodocyclization of γ-
hydroxy-cis-alkenes for the synthesis of enantioenriched 2-substituted tetrahydrofurans 
up to 90% ee (Scheme 5-15). Treatment of V-41 to a solution of (R,R)-Salen-Co(II) 
ligand V-L32, NCS, and iodine promoted enantioselective iodocyclization to generate 
tetrahydrofurans V-42. NCS was required for high enantioselectivites, which the authors 
speculate enhances the acidity of V-L32. The authors also state that this reaction is 
sensitive to the relative amounts of the involved reagents and requires a multi-step 
procedure to properly generate the active catalyst. Furthermore, the synthesis of analogs 
requires the use of different γ-hydroxy-cis-alkenes. 
Scheme 5-15. Enantioselective Iodocyclization 
 
5.53 Project Goals and Previous Work 
 We were interested in developing an asymmetric Pd-catalyzed carboetherification 
reaction that would convert 4-penten-1-ol derivatives V-43 to tetrahydrofuran V-44 
(Scheme 5-16).31 This method would allow for the synthesis of a variety of 
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enantioenriched 2-(arylmethyl)- and 2-(alkenymethyl)tetrahydrofurans from a common 
achiral intermediate.    
Scheme 5-16. Synthetic Strategy 
 
 Initial studies were conducted by Dr. Qifei Yang, who discovered that 
monodentate ligand (S)-NMDPP provided tetrahydrofuran V-44b in 45% ee (Scheme 5-
17).32 However, no chiral ligand gave promising results when unsubstituted 4-penten-1-ol 
(V-43a) was employed as the substrate. My task was to examine other chiral ligands for 
asymmetric carboetherification reactions.  
Scheme 5-17. Preliminary Studies 
 
5.54 Ligand Screen 
Chiral phosphine ligands were initially examined for the coupling of 4-penten-1-
ol (V-43a) and 2-bromonaphthalene. As shown in Table 5-6, bidentate and monodentate 
phosphine ligands did not provide any promising leads for the enantioselective synthesis 
of V-44a.  
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Table 5-6. Phosphine Ligand Screena,b 
+
Br
2 mol % Pd(OAc)2
4 mol % Ligand




























17% yield, 5% ee
a Conditions: Reactions were conducted on a 0.50 mmol scale with 1.0 equiv substrate, 1.2 equiv 2-
bromonaphthalene, 1.2 equiv NaOtBu, 2 mol % Pd(OAc)2, 4 mol % ligand, THF (0.25 M), 65 °C, 12 h. b









In general, optically active phosphoramidite and phosphite ligands were 
ineffective at providing selectivity for the coupling of V-43a and 2-bromonaphthalene 
(Table 5-7). Phosphoramidite ligands such as (S,R,R)-V-L16 and (R)-Siphos-PE (V-L20) 
provided moderate yields of V-44a, but no enantioselectivity was observed. Substrate 
decomposition through oxidation of the alcohol V-43a to the corresponding aldehyde 
may contribute to the low yields in these reactions.33  
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2 mol % Pd(OAc)2
4 mol % Ligand
NaOtBu, THF, 65 C
O *OH
V-43a V-44a
a Conditions: Reactions were conducted on a 0.50 mmol scale with 1.0 equiv substrate, 1.2 equiv 2-
bromonaphthalene, 1.2 equiv NaOtBu, 2 mol % Pd(OAc)2, 4 mol % ligand, THF (0.25 M), 65 °C, 12 h. b












31% yield, 0% ee
 
 We examined V-43b as a substrate for asymmetric carboetherification reactions. 
Bis-phosphine ligands effectively catalyzed the coupling of V-43b and 2-
bromonaphthalene in good yields, but low enantioselectivities. For example, a catalyst 
system of Pd2(dba)3 and (S)-H8-BINAP (V-L36) provided tetrahydrofuran V-44b in 92% 
yield and 0% ee. The H8-BINAP backbone seems to be important for high reactivity in 
these reactions (Table 5-8).  
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Table 5-8. Bidentate Phosphine Ligand Screena,b,c 
 
 As shown below in Table 5-9, a majority of the phosphoramidite and phosphite 
ligands screened provided tetrahydrofuran V-44b in low yields and enantioselectivities. 
However, 2-phenylcyclohexanol derived phosphite ligand V-L10 generated V-44b in 
promising enantioselectivity (53% ee). In cases where no reaction was observed (e.g., 
(S,S,S)-V-L15), conducting the reaction at higher temperatures (110 °C) in toluene did 
not facilitate reaction.  
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Table 5-9. Phosphoramidite and Phosphite Ligand Screena,b,c 
 
A screen of optically active monodentate phosphine ligands yielded promising 
results (Table 5-10). Treatment of V-43b and 2-bromonaphthalene with Pd2(dba)3 and 
(S)-Quinap (V-L27) provided 2-(arylmethyl)tetrahydrofuran V-44b in 83% yield and 
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66% ee. We then decided to examine commercially available Quinap ligand derivatives 
V-L40 and V-L41, but they were not as effective as (S)-Quinap. It is interesting to note 
that the Pd/(S)-Quinap catalyst system was unproductive for 4-penten-1-ol (V-43a), 
which suggests that disubstitution at the C1 position of V-43b is important for 
enantioselectivity. Efforts to improve the ee by conducting the reaction at lower 
temperatures (25 °C) resulted in low conversion.  





























3% yield, 0% ee
V-L41
(R,S)-O-PINAP






37% yield, -30% ee
PPh2
1 mol % Pd2(dba)3
4 mol % Ligand




a Conditions: Reactions were conducted on a 0.25 mmol scale with 1.0 equiv substrate, 2.0 equiv 2-
bromonaphthalene, 2.0 equiv NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand, THF (0.25 M), 65 °C, 12 h. b
Enantiomeric excess was determined by chiral HPLC analysis. c Negative ee values indicate the major




5.55 Summary and Future Directions` 
 In conclusion, we have examined different chiral ligands for the asymmetric 
carboetherification reaction of 4-penten-1-ol (V-43a) or 2-methylhex-5-en-2-ol (V-43b), 
and 2-bromonaphthalene. No chiral ligands were effective for enantioselective 
carboetherification of 4-penten-1-ol (V-43a), as decomposition of the substrate was often 
observed. Conversely, (S)-Quinap ligand provided promsing results for enantioselective 
carboetherifcation of V-43b, generating 2-(naphthyl)tetrahydrofuran (V-44b) in high 
yield (83%) and promising enantioselectivity (66% ee). As shown below in Figure 5-6, 
future studies will involve the synthesis and examination of other closely related ligands 
such as (S)-Quinap derivatives (V-L42),34 (S)-H-MOP (V-L43),35 and (S)-Kenphos (V-
L44),36 which have been effective for asymmetric hydroborations, hydrogenations and 
Suzuki-Miyaura processes respectively.  






 All reactions were carried out in flame-dried glassware under an atmosphere of 
nitrogen. Palladium acetate and tris(dibenzylideneacetone)dipalladium (0) were 
purchased from Strem Chemical Co. and used without further purification. All ligands 
were either purchased from commercial sources (Strem Chemical Co. or Aldrich 
Chemical Co.) or used without further purification, or were synthesized according to 
published procedures.37 4-penten-1-ol (V-43a) was purchased from Aldrich Chemical Co. 
and used without further purification. 1-Allyl-3-ethyl-1-phenylurea (V-12a),9 1-allyl-3-
ethyl-1-phenylurea (V-12b),9 1-allyl-1-benzyl-3-tert-butylurea (V-12c),9 tert-butyl but-3-
enyloxycarbamate (V-20a),17b tert-butyl 2-(2-methylpent-4-en-2-yl)hydrazinecarboxylate 
(V-32a),26 and 2-methylhex-5-en-2-ol (V-43b),31a were prepared according to published 
procedures. Toluene and THF were purified using a GlassContour solvent purification 
system. Yields refer to isolated yields of compounds estimated to be ≥95% pure by 1H 
NMR, GC and/or combustion analysis.  
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Experimental Procedures and Compound Characterization Data 
 




13b). A flame-dried Schlenk tube was cooled under a stream of nitrogen and charged 
with Pd2(dba)3 (3.7 mg, 2 mol % complex, 4 mol % Pd), chiral ligand (6 mol %), 1-allyl-
3-ethyl-1-phenylurea V-12a (50 mg, 0.2 mmol), 2-bromonaphthalene (83 mg, 0.4 mmol) 
and NaOtBu (38 mg, 0.4 mmol). The tube was purged with nitrogen and toluene (1 mL, 
0.2 M) was added via syringe. The mixture was heated to 90 °C with stirring until the 
starting material had been consumed as judged by GC or 1H NMR analysis (ca. 12-15 h). 
The reaction mixture was cooled to room temperature, quenched with saturated aqueous 
NH4Cl (2 ml) and diluted with EtOAc (5 ml). The layers were separated and the aqueous 
layer was extracted with EtOAc (2 x 5 ml). The combined organic layers were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
flash chromatography on silica gel to afford the title compound as a pale yellow solid. 
Mp 138140 °C; 1H NMR (500 MHz, CDCl3) δ 7.817.79 (m, 1 H), 7.767.70 (m, 2 
H), 7.527.44 (m, 5 H), 7.407.20 (m, 3 H), 7.187.12 (m, 3 H), 6.98 (d, J = 15.0 Hz, 
2 H), 4.504.44 (m, 1 H), 4.38 (q, J = 15.0 Hz, 2 H), 3.84 (s, 3 H), 3.24 (t, J = 9.0 Hz, 1 
H), 3.17 (dd, J = 3.0, 13.5 Hz, 1 H), 3.11 (dd, J = 5.5, 9.0 Hz, 1 H), 2.84 (dd, J = 9.0, 
14.0 Hz, 1 H); 13C NMR (125 MHz, CDCl3)  δ 158.3, 156.4, 136.9, 133.8, 133.4, 132.3, 
131.7, 128.5, 128.2, 128.0, 127.9, 127.6, 127.4, 127.3, 127.2, 126.1, 125.6, 123.6, 114.4, 
55.5, 55.1, 47.9, 46.3, 38.2;  IR (film) 1697, 1512, 1246 cm-1; MS (ESI) 423.2061 
(423.2067 calcd for C28H26N2O2, M + H+). The enantiomeric excess for compounds V-
13b in Tables 5-1, 5-2, and 5-3 were determined by chiral HPLC analysis (chiralcel OD-





tert-Butyl 3-(naphthalen-2-ylmethyl)isoxazolidine-2-carboxylate (V-21a). A flame-
dried Schlenk tube was cooled under a stream of nitrogen and charged with Pd2(dba)3 
(1.8 mg, 1 mol % complex, 2 mol % Pd), chiral ligand (4 mol %), 2-bromonaphthalene 
(50 mg, 0.24 mmol) and NaOtBu (19 mg, 0.20 mmol). The tube was purged with 
nitrogen, then a solution of tert-butyl but-3-enyloxycarbamate V-20a (37 mg, 0.2 mmol) 
and toluene (1 mL, 0.2 M) was added via syringe. The mixture was heated to 90 °C with 
stirring until the starting material had been consumed as judged by GC or 1H NMR 
analysis (ca. 12-15 h). The reaction mixture was cooled to room temperature, quenched 
with saturated aqueous NH4Cl (2 ml) and diluted with EtOAc (5 ml). The layers were 
separated and the aqueous layer was extracted with EtOAc (2 x 5 ml). The combined 
organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by flash chromatography on silica gel to afford the title 
compound as a pale yellow oil. Spectroscopic data were consistent with those previously 
reported in the literature.17b The enantiomeric excess for compounds V-21a in Table 5-4 
was determined by chiral HPLC analysis (chiralcel OJ-H, 0.46 cm x 25 cm, 5% 




33a). A flame-dried Schlenk tube was cooled under a stream of nitrogen and charged 
with Pd2(dba)3 (3.7 mg, 2 mol % complex, 4 mol % Pd), chiral ligand (6 mol %), 2-
bromonaphthalene (50 mg, 0.24 mmol) and NaOtBu (38 mg, 0.4 mmol). The tube was 
purged with nitrogen, then a solution of tert-butyl 2-(2-methylpent-4-en-2-yl)hydrazine 
carboxylate V-32a (43 mg, 0.2 mmol) and toluene (1 mL, 0.2 M) was added via syringe. 
The mixture was heated to 90 °C with stirring until the starting material had been 
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consumed as judged by GC or 1H NMR analysis (ca. 12-15 h). The reaction mixture was 
cooled to room temperature, quenched with saturated aqueous NH4Cl (2 ml) and diluted 
with EtOAc (5 ml). The layers were separated and the aqueous layer was extracted with 
EtOAc (2 x 5 ml). The combined organic layers were dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography on silica gel to afford the title compound as a pale yellow oil. 1H NMR 
(500 MHz, CDCl3) δ 7.827.76 (m, 3 H), 7.62 (s, 1 H), 7.44 (dquint, J = 1.5, 7.5 Hz, 2 
H), 7.34 (d, J = 7.5 Hz, 1 H), 4.40 (s, 1 H), 3.58 (s, 1 H), 3.29 (dd, J = 4.0, 13.0 Hz, 1 H), 
2.89 (dd, J = 8.5, 13.0, 1 H), 1.95 (dd, J  = 7.5, 12.5 Hz, 1 H), 1.52 (s, 9 H), 1.14 (s, 3 H), 
0.98 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 156.3, 135.7, 133.4, 132.1, 127.9, 127.7, 
127.6, 127.5, 125.9, 125.4, 80.0, 60.9, 59.8, 47.0, 41.0, 28.4, 25.1, 24.7 (1 peak is missing 
due to incidental equivalence); IR (film) 1716 cm-1; MS (ESI) 363.2034 (363.2043 calcd 
for C21H28N2O2, M + Na+). The enantiomeric excess for compounds V-33a in Table 5-5 
was determined by chiral HPLC analysis (chiralcel OD-H, 0.46 cm x 15 cm, 5% 
iPrOH/hexanes, 0.5 mL/min, λ = 254 nm, RT = 6.6(major) and 7.6(minor) min). 
 
General Procedure for Enantioselective Pd-Catalyzed Carboetherification: 
 
 
2-(Naphthalen-2-ylmethyl)tetrahydrofuran (V-44a). A flame-dried Schlenk tube was 
cooled under a stream of nitrogen and charged with Pd(OAc)2 (2.2 mg,  2 mol % Pd), 
chiral ligand (4 mol %), 2-bromonaphthalene (124 mg, 0.24 mmol) and NaOtBu (58 mg, 
0.6 mmol). The tube was purged with nitrogen, then a solution of 4-penten-1-ol V-43a 
(43 mg, 0.5 mmol) and THF (2 mL, 0.25 M) was added via syringe. The mixture was 
heated to 65 °C with stirring until the starting material had been consumed as judged by 
GC or 1H NMR analysis (ca. 12 h). The reaction mixture was cooled to room 
temperature, quenched with saturated aqueous NH4Cl (2 ml) and diluted with EtOAc (5 
ml). The layers were separated and the aqueous layer was extracted with EtOAc (2 x 5 
ml). The combined organic layers were dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography on silica 
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gel to afford the title compound as a pale yellow oil. Spectroscopic data were consistent 
with those previously reported in the literature.31a The enantiomeric excess for 
compounds V-44a in Tables 5-6 and 5-7 were determined by chiral HPLC analysis 
(chiralcel OJ-H, 0.46 cm x 25 cm, 1% iPrOH/hexanes, 2.0 mL/min, λ = 254 nm, RT = 
11.8(major) and 14.3(minor) min). 
 
 
2,2-Dimethyl-5-(naphthalen-2-ylmethyl)tetrahydrofuran (V-44b). A flame-dried 
Schlenk tube was cooled under a stream of nitrogen and charged with charged with 
Pd2(dba)3 (2.3 mg, 1 mol % complex, 2 mol % Pd), chiral ligand (4 mol %), 2-
bromonaphthalene (104 mg, 0.5 mmol) and NaOtBu (48 mg, 0.5 mmol). The tube was 
purged with nitrogen, then a solution of 2-methylhex-5-en-2-ol V-43b and THF (1 mL, 
0.25 M) was added via syringe. The mixture was heated to 65 °C with stirring until the 
starting material had been consumed as judged by GC or 1H NMR analysis (ca. 12 h). 
The reaction mixture was cooled to room temperature, quenched with saturated aqueous 
NH4Cl (2 ml) and diluted with EtOAc (5 ml). The layers were separated and the aqueous 
layer was extracted with EtOAc (2 x 5 ml). The combined organic layers were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
flash chromatography on silica gel to afford the title compound as a pale yellow oil. 
Spectroscopic data were consistent with those previously reported in the literature.31a The 
enantiomeric excess for compounds V-44b in Tables 5-8, 5-9 and 5-10 were determined 
by chiral HPLC analysis (chiralcel OJ-H, 0.46 cm x 25 cm, 2% iPrOH/hexanes, 1.0 
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